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Caveolin-3 is a muscle specific scaffolding protein with both structural and signaling 
roles.  Lack of caveolin-3 expression has been implicated in limb-girdle muscular dystrophy, 
along with distal myopathy and rippling muscle disease.  These diseases are characterized by 
progressive muscle weakness and muscle wasting.  Nicotinic acetylcholine receptor (nAChR) 
clustering and localization are important for efficient nerve to muscle contractile signal 
transmission.  It is hypothesized that muscle weakness could originate through disrupted nAChR 
clustering, disrupting the efficiency of signaling from the motorneuron to the muscle.  While the 
molecular mechanisms involved in nAChR clustering remain to be fully defined, we hypothesize 
caveolin-3 is important for nAChR clustering and overall neuromuscular junction function. 
Caveolin-3 and the nAChR co-localize and associate evidenced by immunofluorescence 
and immunoprecipitation.  These results were replicated in differentiated wildtype myotubes 
treated with the nAChR clustering agent, neural agrin.  In differentiated caveolin-3 null 
myotubes, agrin treatment yields a 60% reduction in nAChR clusters as compared to agrin 
treated wildtype myotubes.  Agrin induces nAChR clustering, through activation of muscle 
specific kinase (MuSK) and downstream through Rac-1 activation.  In differentiated wildtype 
myotubes, Rac-1 activation peaks at 1 hour of agrin treatment, while in differentiated caveolin-3 
null myotubes there is dramatically reduced Rac-1 activation upon agrin treatment.  
Immunoprecipitation of MuSK shows that caveolin-3 and MuSK association peaks at 1 hour of 
LGMD-1C: ROLE OF CAVEOLIN-3 IN NEUROMUSCULAR JUNCTION 
STRUCTURE AND FUNCTION 
Michael P. Hezel, Ph.D. 
University of Pittsburgh, 2009
 
 v 
agrin treatment in wildtype cells.  This corresponds to the peak of MuSK phosphorylation which 
also occurs at 1 hour.  Agrin induced MuSK phosphorylation was decreased more significantly 
than the overall decrease in MuSK expression in the caveolin-3 null cells as compared to the 
wildtype results.  These results indicate a role for caveolin-3 in efficient nAChR clustering. 
Electromyography studies in anesthetized mice indicated lengthened latencies of the 
muscle action potential in the caveolin-3 null mice as compared to wildtype mice.  There were 
also decreased overall electromyography (EMG) amplitude and EMG area under the curve in 
caveolin-3 null mice.  Comparison of contractile strength in wildtype and caveolin-3 null animals 
indicated tetanic contractions to be less stable in the caveolin-3 null animals, though there was 
late potentiation in actual contractile strength. 
Lack of caveolin-3 affects the neuromuscular junction formation and transmission 
without affecting overall contractile strength.  This research opens a novel view, that correct 
neuromuscular junction formation and neuromuscular transmission is important in the 
development of muscular dystrophies. 
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1.0  INTRODUCTION 
1.1 MUSCULAR DYSTROPHY 
Muscular dystrophies are a class of diseases characterized by progressive weakness and 
degradation of voluntary muscles.  The first type of muscular dystrophy described was Duchenne 
Muscular Dystrophy (DMD) characterized by early onset almost exclusively in males and 
resulting in patient death in the second decade of life (Bogdanovich, Perkins et al. 2004).  
Edward Meryon first identified DMD as resulting in muscle degradation and fat replacement 
without nervous system defects as identified by lack of lesions in the nervous system by gross 
examination (Emery and Emery 1993).  Dr. Meryon postulated that the disease resulted from 
breakdown of the sarcolemma (Emery and Emery 1993).  The disease was later named 
Duchenne’s Muscular Dystrophy after Guillame Benjamin Amand Duchenne published his 
research describing the same disease (Bogdanovich, Perkins et al. 2004). 
Since then, eight other forms of muscular dystrophy have been documented, of which 
some have associated cardiac and mental developmental defects, but all present with progressive 
muscle weakness and wasting (Table 1).  The advent of modern molecular techniques has 
allowed for documentation of mutated genes associated with these diseases, providing a 
“snapshot” into disease development.  While some types of muscular dystrophy result from 
singular genetic changes, other dystrophy phenotypes result from one of a number of mutated 
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Table 1. Muscular Dystrophies 
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genes.  The most common forms of muscular dystrophy arise from genetic deficiencies of the 
muscle protein dystrophin, collectively known as dystrophinopathies.  DMD is the most severe 
form of dystrophinopathy, while Becker Muscular dystrophy is a milder form of 
dystrophinopathy (Emery and Emery 1993).  Facioscapulohumeral dystrophy and myotonic 
dystrophy result from genetic changes that do not change translated genetic coding. (Bickmore 
and van der Maarel 2003).  Emery-Dreifuss Muscular Dystrophy and Distal Muscular Dystrophy 
phenotypes result from changes in one of a number of gene sequences or the processing of the 
encoded protein (Emery and Emery 1993; Udd and Griggs 2001).  Limb-Girdle Muscular 
Dystrophy is a form of muscular dystrophy affecting proximal limb and girdle muscles and has 
over 20 altered gene expression subtypes (Emery and Emery 1993).  To date, there is no cure for 
muscular dystrophies, but medications and therapy can slow the course of the disease. 
1.2 LIMB-GIRDLE MUSCULAR DYSTROPHY 
The name Limb-Girdle Muscular Dystrophy (LGMD) is derived from the muscles most 
affected by the disease.  The proximal limb muscles are the muscles afflicted in this disease, 
affecting movement.  Degradation of the same muscle groups is the commonality in LGMD, 
although the subtypes vary in the time of onset, speed of progression, and severity (Mathews and 
Moore 2003).  Due to the many genetic variations of LGMD, the classification is organized into 
two categories, based on whether the gene mutation is dominant (1) or recessive (2), and 
subsequently by the gene involved (Table 2) (Laval and Bushby 2004; Daniele, Richard et al. 
2007).  Not only do the subtypes have different progression characteristics, but even related  
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Table 2. Limb Girdle Muscular Dystrophies  
TYPE GENE ROLE FUNCTION 
1A Myotilin Structure z-disks 
1B Lamin A and Lamin C Differentiation Nuclear envelope 
1C Caveolin-3 Structure Membrane 
1D Chromosome 7   
1E Chromosome 6   
1F Chromosome 7   
1G Chromosome 4   
2A Calpain-3 Calcium dependant signaling Cytoplasmic 
2B Dysferlin Membrane Repair T-tubules, membrane 
2C Gamma-Sarcoglycan Structure  Membrane 
2D Alpha-Sarcoglycan Structure  Membrane 
2E Beta-Sarcoglycan Structure  Membrane 
2F Delta-Sarcoglycan Structure  Membrane 
2G Telethonin/Titin-Cap Regulation, Development Z-disks 
2H TRIM 32 E3 ubiquitin ligase Cytoplasmic 
2I FKRP Glycosyltransferase Golgi 
2J Titin Myofibrillogenesis Myofibrils 
2K POMT1 Glycosyltransferase  
2L Fukutin Glycosyltransferase  
2M POMGn1 Glycosyltransferase  
2N POMT2 Glycosyltransferase  
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patients with the same mutation, have differences in disease onset and progression.  LGMD-1C, 
is an autosomal dominant form of LGMD, resulting from caveolin-3 gene mutations (Minetti, 
Sotgia et al. 1998).  Patients affected with LGMD-1C generally have one faulty caveolin-3 gene 
inherited from one parent. HyperCKemia, distal myopathy and rippling muscle disease are other 
diagnoses associated with caveolin-3 mutations (Woodman, Sotgia et al. 2004). 
1.3 CAVEOLINS 
Caveolin-3 belongs to a family of proteins known as caveolins, with three isoforms, 
caveolin-1, caveolin-2 and caveolin-3.  The caveolins are implicated in the formation of 
ultrastructural plasma membrane invaginations 50 – 100nm in diameter, called caveolae (Razani 
and Lisanti 2001). These structures are characterized by high cholesterol and sphingolipid 
content.  Caveolae were first identified in the mid 20th century by electron microscopy (Stan 
2005).  In the following 4 decades, biochemical techniques associated caveolae with roles in 
protein localization, organization and trafficking.  These findings led to the postulation of the 
“Caveolae Signaling Hypothesis,” which propounded that by compartmentalizing signaling 
molecules, caveolae regulate signal transduction (Song, Scherer et al. 1996).  By use of modern 
molecular techniques, caveolin-1 was identified as an oncogenic gene important in the formation 
of caveolae and a substrate for v-Src (Lisanti, Scherer et al. 1994).  Since then, caveolin-1 has 
been identified to have both oncogenic and tumor suppressor properties.   Subsequently, 
caveolin-2 and caveolin-3 were identified and the role of caveolins in processes previously 
attributed to caveolae by earlier electron microscopy, were confirmed (Scherer, Okamoto et al. 
1996; Tang, Scherer et al. 1996).  The caveolae structure results from either 14-16 hetero-
 6 
oligomers of caveolin-1 and caveolin-2 or homo-oligomers in the case of caveolin-3 (Williams 
and Lisanti 2004).  While caveolin-1 and caveolin-2 have been identified in many cell types such 
as fibroblasts, adipocytes, endothelial and epithelial cells, caveolin-3 is muscle specific and 
expressed in skeletal, cardiac and smooth muscle (Razani and Lisanti 2001).  Caveolin-1, 2 and 3 
have all been identified in arterial and bladder smooth muscle (Segal, Welsh et al. 1999; 
Woodman, Cheung et al. 2004).   
1.4 CAVEOLIN-3 
Caveolin-3, a muscle specific caveolin isoform, is initially expressed during myoblast 
differentiation into myotubes.  Caveolin-1 is first expressed in myoblasts, and downregulated 
during myoblast differentiation (Parton, Way et al. 1997).  After 48 hours of myoblast 
differentiation, caveolin-3 expression is initiated and replaces caveolin-1 expression.  Caveolin-3 
is located throughout the sarcolemma and is important for myoblast fusion into myotubes 
(Volonte, Peoples et al. 2003).  In the cell, caveolin-3 performs structural, signaling, and 
trafficking capacities. 
Caveolin-3 has been shown to interact with structural features and proteins in muscle 
cells, such as the dystrophin-glycoprotein complex, dysferlin, the T-tubules and cytoskeletal 
elements (Song, Scherer et al. 1996; Matsuda, Hayashi et al. 2001; Volonte, Peoples et al. 2003).  
The dystrophin-glycoprotein complex consists of many proteins and serves to connect the 
extracellular matrix to the actin cytoskeleton (Michele and Campbell 2003).  Dystrophin, a major 
component of this conglomeration, binds beta-dystroglycan which spans the sarcolemma and 
through binding alpha-dystroglycan associates with the extracellular matrix (Lapidos, Kakkar et 
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al. 2004). Immunoprecipitation with a dystrophin antibody and blotting for caveolin-3 indicated 
association of caveolin-3 and dystrophin (Song, Scherer et al. 1996).  Research on caveolin-3 
and beta-dystroglycan suggests association through immunofluorescence, sucrose gradients and 
immunoprecipitation methods (Sotgia, Lee et al. 2000).  The dystrophin-glycoprotein complex 
also consists of the transmembrane sarcospan protein and sarcoglycan family, and cytoplasmic 
proteins, dystrobrevin and the syntrophins.  Many of these proteins are implicated in other 
LGMD subtypes. 
Dysferlin has been identified as important in membrane repair after sheer stress (Bansal, 
Miyake et al. 2003).  Interestingly, removal of caveolin-3 from the plasma membrane leads to 
increased intracellular localization of dysferlin (Capanni, Sabatelli et al. 2003; Hernandez-
Deviez, Howes et al. 2008).  Defects in dysferlin localization lead to concomitant disruption in 
caveolin-3 expression and localization found in LGMD-2B (Matsuda, Hayashi et al. 2001; 
Walter, Braun et al. 2003).   
Caveolin-3 interacts with cytoskeletal proteins alpha-tubulin and actin.  Caveolin-3 binds 
alpha-tubulin and loss of caveolin-3 leads to a diffuse and disoriented localization as identified in 
immunofluorescent staining.  Likewise, caveolin-3 and actin co-localize.  Lack of caveolin-3 
expression in null myotubes reduces actin tubule localization along the plasma membrane and 
induces random localization of actin fibers (Volonte, Peoples et al. 2003). 
The transverse tubules (T-tubules) are a membranous myofibular structure and the site of 
excitation contraction coupling (Flucher 1992).  Caveolin-3 localizes to the T-tubules prenatally, 
although there are conflicting reports on caveolin-3 localization at the T-tubules in mature 
myotubes (Parton, Way et al. 1997; Ralston and Ploug 1999).  A recent manuscript supports the 
notion of caveolin-3 continual co-localization in the T-tubules, through sarcolemma removal 
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from the myotube and immunofluorescent analysis (Murphy, Mollica et al. 2009).  The T-tubules 
have an aberrant structure in caveolin-3 null myotubes as identified by electron microscopy 
(Galbiati, Engelman et al. 2001). 
Several receptors have also been shown to associate with caveolin-3.  The insulin 
receptor has been shown to bind caveolin-3 and traffic the activated receptor to the interior of the 
cell.  This translocation and associated signaling pathway induces the translocation of the insulin 
regulated glucose transporter (GLUT-4) from intracellular vesicles to the plasma membrane 
(Fecchi, Volonte et al. 2006).  Essential receptor tyrosine kinases, platlet derived growth factor 
receptor (PDGF-R) and epidermal growth factor receptor (EGF-R) have their 
autophosphorylation inhibited by caveolin-3 binding (Couet, Sargiacomo et al. 1997; Yamamoto, 
Toya et al. 1999).  Caveolin-3 also inhibits autophosphorylation of the activin like receptor 
kinases 4 and 5 (ALK4 and ALK5), which respond to the ligand myostatin, important in negative 
regulation of muscle growth (Ohsawa, Hagiwara et al. 2006). 
Caveolin-3 also plays a key role in intracellular signaling crucial for cellular function.  As 
with PDGF-R and EGF-R activation, caveolin-3 inhibits autophosphorylation of c-src, of the src 
family kinases.  In accordance with these findings, c-src has increased activation in caveolin-3 
mutant or null cells (Venema, Ju et al. 1997; Smythe, Eby et al. 2003).   By directly binding the 
nitric oxide synthase proteins, caveolin-3 inhibits nitric oxide production by all three nitric oxide 
synthases (Garcia-Cardena, Martasek et al. 1997; Venema, Ju et al. 1997).  Oxidative stress 
activates movement of PI3Kinase, PDK1 and AKT signaling proteins into caveolar membranes 
with subsequent caveolin-3 association. Lack of caveolin-3 expression or inhibition to one of the 
above proteins induced abrogation of these caveolin-3 associations, and increased oxidative 
stress induced apoptosis (Smythe and Rando 2006). 
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Even though caveolin-3 plays varied roles in muscle structure and signaling, few 
laboratories have looked at caveolin-3 role in neuromuscular junction formation and function.  
Proper organization of the neuromuscular junction is essential for neuromuscular transmission 
required for movement. 
1.5 NEUROMUSCULAR JUNCTION 
As implied, the neuromuscular junction is where the nerve and muscle interact.   The 
main function of this structure is conducting signals from the nerve to the muscle, inducing 
movement, important to the survival of all animals.  While the neuromuscular junction has often 
served as a model for nerve to nerve signal transmission due to its size and accessibility, it is in 
its own right a complex structure, requiring myriad proteins and signals for proper development 
and efficient function. 
The neuromuscular junction also known as the synapse, consists of three parts: 1) the 
nerve terminal, 2) the synaptic cleft, and 3) the muscle (Figure 1)(Hughes, Kusner et al. 2006).  
The nerve terminal, also known as the presynaptic junction, is where the action potential 
traveling down the axon terminates inducing the release of acetylcholine (ACh) from 
intracellular vesicles.  The synaptic cleft is the space between the nerve and the muscle across 
which ACh travels and contains extracellular proteins that modulate this signaling.  The muscle 
membrane juxtaposed to the nerve terminal, also known as the post-synaptic junction, is where 
nerve released ACh binds acetylcholine receptors located on the muscle membrane initiating a 
depolarization cascade resulting in contraction (Sanes and Lichtman 2001). 
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Figure 1. Diagram of the Neuromuscular Junction Organization 
The neuromuscular junction consists of the nerve terminal, the synaptic cleft and the muscle membrane.  The 
organization of the nerve and muscle along with the correct localization of associated proteins is important for 
proper neuromuscular junction transmission and muscle movement.  White circles in the nerve terminal represent 
vesicles containing acetylcholine.  Nicotinic acetylcholine receptors are represented by blue barrels and voltage 
gated sodium channels are represented by green dots.  
  
The organization of the neuromuscular junction is very complex with signaling between 
the nerve and muscle and vice versa organizing the pre- and post-synaptic membrane and 
extracellular proteins in the synapse.  This intercellular signaling refines the neuromuscular 
junction, increasing the efficiency of neuromuscular transmission (Witzemann 2006).  There are 
many prenatal and postnatal changes modulating the organization of the acetylcholine receptor.  
These changes involve protein expression, protein association and structural changes leading to 
increased efficiency of acetylcholine receptor function. 
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1.6 ACETYLCHOLINE RECEPTOR 
The two types of acetylcholine receptors present in humans and mice are the nicotinic 
and muscarinic acetylcholine receptors, named after their respective agonists.  The muscarinic 
acetylcholine receptors (mAChR) are G-protein-coupled receptors initiating protein based 
signaling, through small g-proteins (Wessler and Kirkpatrick 2008).  These receptors, found in 
the autonomic nervous system, are important in controlling visceral functions.  Nicotinic 
acetylcholine receptors (nAChR) are ligand-gated ion channels, which allow sodium influx upon 
ACh binding.  This ion influx activates a number of voltage fluctuations in the muscle leading to 
contraction.  The speed of this signaling is much faster than that of muscarinic acetylcholine 
receptors due to the rapidity of depolarization (Madhavan and Peng 2005).  The nicotinic 
acetylcholine receptor (nAChR) is essential in nerve to muscle signaling, resulting in muscle 
contraction. 
1.7 NICOTINIC ACETYLCHOLINE RECEPTOR 
The nicotinic acetylcholine receptor (nAChR) in muscle is a hetero-pentameric receptor.  
It is located on the muscle membrane and when bound by the ligand acetylcholine (ACh), 
induces an influx of sodium.  The nAChR initially formed at the neuromuscular junction, also 
known as the fetal form, consists of 2α, 1β, 1γ and 1δ subunits.  During neuromuscular junction 
maturation, receptors with the γ subunit are replaced by receptors with the ε-subunit, conferring 
receptor stability through increased half-life (Sanes and Lichtman 1999).  Each subunit consists 
of 4 trans-membrane domains that associate with the other subunit transmembrane domains to 
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form a hydrophilic pore through which sodium ions pass (Wanamaker, Christianson et al. 2003).  
The association of 2 acetylcholine molecules to the receptor opens the channel by inducing 
removal of the transmembrane domain linkers from blocking the channel.  The nAChR initially 
clusters at a concentration of 1000 receptors/µm2 which increases to approximately 10,000 
receptors/µm2 in the mature neuromuscular junction (Hughes, Kusner et al. 2006).  Since nAChR 
localization to the neuromuscular junction is essential for movement, nAChR organization and 
function has been extensively studied. 
The muscle, before being innervated, localizes nAChR clusters along the midsection of 
the myotubes.  This intrinsic acetylcholine receptor clustering occurs even before neuronal 
contact to the myotubes (Figure 2A).  Around prenatal day 14 in the mouse, the nerve growth 
cone reaches the myotube.  The nerve releases a peptide called agrin which induces the re-
localization of the receptors already at the midsection of the myotubes to areas directly 
juxtaposed to the growing nerve (Sanes and Lichtman 2001).  While there are other factors 
implicated in this reorganization, such as neuregulin, laminin and acetylcholine, neuronal agrin is 
the most potent clustering molecule (Hughes, Kusner et al. 2006).  Agrin induces a signaling 
cascade in the muscle which induces localization and organization of the acetylcholine receptor 
at the neuromuscular junction.  By birth, the neuromuscular junction formation is further 
modified to one nerve terminal per myotube (Figure 2B). 
Upon birth, the neuromuscular junction undergoes further modification leading to 
increased efficiency of synaptic transmission.  During this remodeling, folds form at the post-
synaptic neuromuscular junction with the acetylcholine receptor localized at the crests and the 
voltage gated sodium channels located in the troughs of the folds.  This differential localization 
provides for stronger and faster muscle depolarization for efficient contractile response.  In mice, 
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it takes approximately a month after birth for full maturation of the neuromuscular junction 
(Figure 2C)(Sanes and Lichtman 2001). 
 
Figure 2. Neuromuscular Junction Development 
The muscle membrane remodels over time to increase neuromuscular junction transmission efficiency. (A) In pre-
innervation, the muscle has intrinsic nAChR localization at the mid-section of the myotube before nerve association 
with the muscle.  (B)  The nerve contacts the muscle and at birth one nerve has innervated each myotube and is able 
to function but not at full efficiency.  The nAChR are located juxtaposed to the nerve terminal.  (C) During postnatal 
development, folds form at the muscle membrane with the nAChR located at the crests (blue barrels) and the sodium 
channels (green dots) at the troughs of the myotube.  These folds make neuromuscular transmission efficient and the 
neuromuscular junction (NMJ) in mice reaches maturity around 1 month of postnatal development.  
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The nAChR has low expression in myoblasts but is upregulated during differentiation by 
myogenic factors, particularly myogenin (Macpherson, Cieslak et al. 2006).  During myofiber 
formation, the subsynaptic nuclei increase transcription of nAChR subunits, while transcription 
of nAChR subunits is suppressed at extrasynaptic nuclei (Macpherson, Cieslak et al. 2006).  
Muscle specific kinase (MuSK) and receptor associated protein of the synapse (rapsyn) 
are two proteins found to be essential to nAChR clustering.  Abrogation of expression of either 
of these proteins, results in mice that die at birth due to lack of functional neuromuscular 
junctions in the diaphragm required for breathing (Gautam, DeChiara et al. 1999; Wiesner and 
Fuhrer 2006).  Many other proteins have been shown to play a role in clustering, including src 
family of tyrosine kinases, 14-3-3, geranyl geranyl transferase I, abl, dishevelled-1, Doc-7, Tid1, 
Rac1 and Rho GTPases, Pak1 and APC1 (Weston, Yee et al. 2000; Mohamed, Rivas-Plata et al. 
2001; Luo, Wang et al. 2002; Luo, Je et al. 2003; Wang, Jing et al. 2003; Weston, Gordon et al. 
2003; Strochlic, Cartaud et al. 2004; Weston, Teressa et al. 2007; Linnoila, Wang et al. 2008).  
Recent research discovered LDL related receptor 4 (LRP4) as an agrin binding protein which 
associates and precedes MuSK activation in the clustering signaling cascade (Kim, Stiegler et al. 
2008; Zhang, Luo et al. 2008).  The agrin induced signaling cascade will be discussed in further 
detail in chapter 4. 
Since localization and stability are important for reliable signaling through the nAChR, 
research has focused on nAChR association with structural molecules.  Vinculin, talin, paxillin, 
and focal adhesion kinase have been shown to link the receptor to actin and the cytoskeleton 
(Madhavan and Peng 2005).  The receptor also associates with the dystrophin-glycoprotein 
complex (Banks, Fuhrer et al. 2003).  This complex consists of strong associations between 
dystrophin, alpha and beta dystroglycan, sarcoglycans, dystrobrevin, syntrophin and nitric oxide 
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synthase (Michele and Campbell 2003).  Utrophin replaces dystrophin in the dystrophin-
glycoprotein complex at the post-synaptic membrane (Banks, Fuhrer et al. 2003). Rapsyn has 
been suggested to mediate nAChR linkage with beta-dystroglycan, though other research shows 
direct nAChR and beta-dystroglycan association (Banks, Fuhrer et al. 2003).  Dystroglycan, 
dystrobrevin, and syntrophin mutants each exhibit disruption of neuromuscular junction 
organization. 
1.8 RATIONALE 
Diagnosis of muscular dystrophy occurs when patients are symptomatic with muscle 
weakness and degrading muscle fibers as determined by histology.  This occurs after periods of 
unhindered movement in all but the most severe muscle pathologies.  These dystrophies vary in 
severity and onset even when evolving from the same underlying genetic mutations.  We 
hypothesize that this phenotypic variability could result from structural and/or functional 
changes at the neuromuscular junction, and be modulated by differences in patient movement 
over their lifetime.  Following this line of thought the symptoms and diagnosis could evolve 
from contractile signaling degrading past a threshold in muscle signaling.   Pre-symptomatic 
compensation may result from intrinsic supramaximal signaling involved in muscle contraction.  
Using a model for limb-girdle muscular dystrophy subtype 1C, we will assess the role of the 
neuromuscular junction structure and function in development of one form of muscular 
dystrophy. 
The following research explores the hypothesis that loss of caveolin-3 expression leads to 
post-synaptic structure and function changes influencing muscular dystrophy development.   This 
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hypothesis will be assessed using caveolin-3 null mice and derived myoblast culture in 
comparison to wildtype mice and derived myoblast culture. Caveolin-3 null mice and cells are a 
model system for LGMD-1C, a muscular dystrophy subtype resulting from dominant negative 
mutations of caveolin-3.  This research using caveolin-3 null and wildtype mice and 
differentiated muscle cultures will analyze differences in formation of the post-synaptic 
neuromuscular junction at both the gross and molecular level and also neuromuscular junction 
function and contractile strength in vivo. 
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2.0  MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 Reagents 
Antibodies and their sources: nicotinic acetylcholine receptor alpha (clone 26), caveolin-3 (clone 
26), HRP-conjugated goat anti-rabbit, phosphotyrosine (clone PY20), and Rac1 (clone 102), 
were purchased from BD transduction laboratories.  Caveolin-3 (n-18), and dishevelled-1 (3F12), 
MuSK (C-19) were purchased from Santa Cruz Biotechnologies. MuSK and Rac1 (clone 23A8) 
were purchased from Affinity Bioreagents.  Nicotinic acetylcholine receptor (clone 35) and beta-
tubulin III (TUJ1) were obtained from Covance, while Alexa Fluor 647 conjugated alpha-
bungarotoxin and unbound alpha-bungarotoxin were purchased from Invitrogen. Anti-
phosphotyrosine (clone 4G10, Upstate Cell Signaling), and HRP conjugated Goat anti-mouse 
(Pierce) were also purchased.  The construct for the GST p21 activated kinase binding domain 
fusion protein was kindly provided by Daniel Altschuler.  pSM constructs of the nAChR 
subunits were kindly provided by Z. Z. Wang.  All chemicals were purchased from Sigma, or 
Fisher Scientific. 
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2.1.2 Cell Culture 
The wildtype and caveolin-3 null myoblast cell cultures were obtained as previously described 
(Volonte, Peoples et al. 2003).  The myoblasts were grown at 33°C under a proliferation media 
Ham’s F-10 containing 20% FBS, 2mM L-glutamine, 100 Units/ml penicillin, and 100 µg/ml 
streptomycin.  Before using proliferation media, bFGF (2.5ng/ml) and gamma-interferon 
(50U/ml) were added to the media.  To differentiate myoblasts into myotubes, cells at 
approximately 90% confluence had their media changed to differentiation media, DMEM 
containing 2% horse serum, 2mM l-glutamine, 100 units/ml penicillin and 100 µg/ml 
streptomycin at 37°C.  To induce acetylcholine receptor clustering, 10ng/ml rat agrin (R & D 
Biosystems) was added to differentiation media.  The oncogenic Ras cell line is a 3T3 line 
derivative expressing stable constitutively active RasG12V (Koleske, Baltimore et al. 1995).  
Overexpression of Ras abrogates Caveolin-1 expression removing all caveolin protein 
expression.  Ras and 3T3 cells are grown in DMEM with 10% donor bovine serum, 2mM l-
glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin. 
2.1.3 DNA Constructs 
A wildtype MuSK and two MuSK constructs with mutated caveolin binding domains were 
inserted into a pCMV-HA vector.  Using cDNA, and MuSK primers (5’- ccg gcc gtc gac aag aga 
gct cgt caa cat tcca and 3’- cc ggc cgc ggc cgc tta gac act cac agt tcc ctc), MuSK was amplified, 
and subsequently cut with Sal I and Not I and ligated into the vector.  The mutants were then 
produced using internal primers changing aromatic residues to alanines with the original external 
primers.  The primers for Mutant A were 5’- gat gtg gcg gcc gct ggc gtg gtc ctc gcg gag atc and 
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3’- gat ctc cgc gag gac cac gcc agc ggc cgc cac atc.  The primers for Mutant B were 5’- gag atc 
gcc tcc gct ggc ctg cag ccc gcc gct ggg atg and 3’- cat ccc agc ggc ggg ctg cag gcc agc gga ggc 
gat ctc.  The two mutated fragments were amplified with the WT MuSK vector to produce the 
full mutated DNA.  This was also inserted into the pCMV-HA vector.  A myc-tagged nAChR-
alpha subunit construct was inserted into the pCAGGs vector.  Using cDNA and nAChR primers 
(5’ - ggc cgg gaa ttc atg gag ctc tcg act gtt ctc and 3’- ggc cgg gaa ttc tta att cag atc ttc ctc gct gat 
cag ttt ctg ttc gcc gcc tcc ttg ttg atg taa ctc aag), nAChR-alpha-myc was amplified, cut with 
EcoRI and ligated into a dephosphorylated pCAGGs vector. 
2.2 METHODS 
2.2.1 Immunofluorescent Staining 
2.2.1.1 Tissue Sections 
Quadriceps tissue from 22 month old wildtype and caveolin-3 null mice were dissected, snap 
frozen and embedded in OCT.  Cross-sections, 5 micrometers thick, were placed on frosted 
slides, 2 sections per slide and kept frozen until stained.   The slides were rehydrated in 
phosphate buffered saline with calcium and magnesium (PBS-CM) and rinsed with PBS-CM 
with 0.1% Triton-X-100 (PBS-CM-T).  The tissue on the slide was placed in monoclonal mouse 
anti-nAChR-alpha and polyclonal anti-goat anti-caveolin-3 antibodies diluted 1:500 in PBS-CM-
T and incubated at room temperature for 3 h.  Slides were washed 3X in PBS-CM-T for 10 min 
each.  Slides were incubated for 2 h in secondary antibodies, at a 1:1000 dilution in PBS-CM-T.  
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Slides were washed 3X in PBS-CM-T for 10 min each, rinsed in phosphate buffered saline (PBS) 
and a coverslip mounted over the tissue using anti-fade (Invitrogen) and sealed with nail-polish. 
2.2.1.2 Cells on Coverslips 
Cells were grown on uncoated cover slips and treated as required for the staining experiment.  
The cells were washed 3x in PBS-CM and fixed with 2% paraformaldehyde in PBS solution for 
30 min.  Cells were permeabilized with PBS-CM-T for 10 min and peroxides quenched with 
ammonium chloride in PBS-CM for 10 min followed by a rinse with PBS-CM-T.  The addition 
of the primary antibodies and subsequent steps were performed as described above for the tissue 
sections with the exception that the coverslips were mounted onto slides. 
2.2.1.3 Whole Mount Staining 
This protocol is adapted from Lin et al. 2005.  After dissecting the diaphragm tissue or EDL 
muscle from the mouse and washing it in PBS, it was fixed in 2% paraformaldehyde in 0.1% 
phosphate buffered saline (pH 7.3) overnight at 4°C.  The tissue was rinsed in PBS (pH 7.3) and 
then incubated in a 0.1M glycine in PBS for 1 h.  The tissue was rinsed again in PBS and then 
incubated in 0.5% Triton-X-100 solution in PBS for 1 h.  The muscle was then blocked in 
dilution buffer (500mM NaCl, 0.01M phosphate buffer, 0.01% Thimerosal) overnight at 4°C. 
The tissue was then incubated with primary antibodies, caveolin-3 (1:500) and beta-tubulin III 
(1:500) in dilution buffer overnight at 4°C.  The tissue was rinsed 3X with 0.5% Triton-X-100 in 
PBS for 1 h each and incubated overnight at 4°C with fluorescent secondary antibodies (1:1000) 
and Alex 647 alpha-bungarotoxin (1:500) in dilution buffer.  The tissue was then washed 3X in 
0.5% Triton-X-100 solution in PBS for 1 h each.  The tissues were rinsed one last time in PBS, 
mounted on a slide with antifade solution and analyzed by confocal microscopy. 
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2.2.1.4 Analysis of nAChR Clustering 
Wildtype and caveolin-3 null cells were grown on uncoated glass cover slips, differentiated for 7 
days and treated with agrin for 24 hours.  The cells were stained for caveolin-3 and nAChR as 
above.  The samples were analyzed by confocal microscopy, images were taken and the lengths 
of the clusters were measured and averaged.  The clusters per field were also counted in triplicate 
and averaged.  Statistical analysis was performed using Student’s T-test. 
2.2.2 Protein Association Procedures 
2.2.2.1 Immunoprecipitation 
Cells were washed 2X in cold PBS, scraped in lysis buffer solution and lysed by pipeting 30 
times.  Tissue was placed in lysis buffer and mechanically homogenized using a tissue tearor 
(Biospec Products Inc.) for 30 s.  Lysis buffer consisted of 10mM Tris-HCl pH 8.00, 150mM 
NaCl, 5mM EDTA, 1% Triton-X-100, 6mM of n-octyl glucoside (Roche) and one complete 
protease inhibitor tablet (Roche) per 10ml of solution.  The samples were mixed on a 
hematology/chemistry mixer (Fisher Scientific) at 4°C for 1 h.  The insoluble material was 
precipitated by centifugation and the supernatant was collected.  The samples were pre-cleared 
with 10 µl of Protein A Sepharose slurry (1:1 beads:lysis buffer) and the protein content 
measured by BCA assay.  Samples were normalized to have the same protein content and 
volume, and 10% of normalized solution was collected as totals. The immunoprecipitating 
antibody and Protein A Sepharose (Amersham Biosciences) beads were then added to the 
samples.  The samples were put on a hematology/chemistry mixer overnight at 4°C.  Beads were 
washed 3X with lysis buffer and once with 50mM Tris-HCl.  Laemmli Buffer was added to the 
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beads, which were vortexed and incubated at room temperature for 10 min.  Samples and 
corresponding totals were analyzed by western blotting. 
2.2.2.2 Sequential Immunoprecipitation 
Followed the immunoprecipitation protocol up to the addition of Laemmli Buffer,  0.5% sodium 
dodecyl sulfate (SDS) solution was added to the beads and incubated at 50°C for 10 min.  The 
supernatant was collected and diluted to 0.1% SDS in lysis buffer before continuing with the 
second immunoprecipitation.  At the end of the experiment, the SDS removal of the proteins 
from the beads was performed again selectively remove the proteins leaving the antibody bound 
to the beads.  Results were analyzed by western blot. 
2.2.2.3 Binding of GST-Fusion Protein to Glutathione bound Sepharose Beads 
GST constructs in BL21 bacteria were grown at 37°C in ampicillin containing LB to an Optical 
Density between 0.3 and 0.6.  IPTG was added to achieve a final concentration of 0.5mM and 
left shaking at 37°C for 2 h.  The bacteria were centrifuged and washed in 150mM NaCl, 7.5mM 
Tris pH 8.00, and 3mM EDTA (STE) and resuspended in 10ml STE.  10µg/ml lysozyme was 
added to the bacterial solution and incubated on ice for 15 min.   DTT (1M) and 10% n-lauryl 
sarkosyl were added to final concentrations of 5mM and 1.5%, and a crushed minicomplete 
protease inhibitor tablet was also added.  Cells were homogenized using the tissue tearor at 
medium speed for 30 s and centrifuged for 20 min to remove insoluble material.  The supernatant 
was collected and 20% Triton-X-100 in STE added to a final concentration of 2%.  GST beads 
(500µl) were pre-washed 3X in STE buffer and then added to the GST-fusion protein solution.  
The beads were bound to the fusion protein on a hematology/chemistry mixer overnight at 4°C.  
The next day the beads were washed in STE with 1% Triton-X-100 and saved for the 
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experiment.  The amount of protein fused to the beads was analyzed by running on a mini-gel 
and staining with Coomassie Blue stain. 
2.2.2.4 Rac1 Pull-down using GST-PBD bound Glutathione beads 
Cells were washed 2X in cold PBS, scraped, and collected in lysis buffer, consisting of 50 mM 
Tris-HCl, 0.5% sodium deoxycholate, 0.1%SDS, 150mM sodium chloride, 10mM magnesium 
chloride, 1% Triton-X-100 and one Complete-Mini protease tablet per 10ml buffer for the Rac-1 
pulldown.  Cells were resuspended and centrifuge tube put on a hematology/chemistry mixer for 
1 h.  Insoluble material was precipitated by centrifugation and the supernatant collected.  The 
samples were precleared with unbound GST beads to remove endogenous glutathione binding 
proteins.  Sample protein expression was compared using the BCA protein assay.  The same 
amount of protein and volume were put in each sample and 10% taken for total protein analysis.  
GST-PBD bound glutathione beads were then added to each sample and put on rotation 
overnight at 4°C.  The beads were washed 3X with lysis buffer without SDS and sodium 
deoxycholate.  Laemmli Buffer was added to the beads, which were vortexed and incubated at 
room temperature for 10 min.  Samples and corresponding totals were analyzed by western 
blotting. 
2.2.2.5 Binding of alpha-bungarotoxin to cyanogen bromide activated sepharose beads 
Unlabelled alpha-bungarotoxin was bound to cyanogen bromide activated sepharose beads 
(Sigma) following the protocol provided and modified for use without a column.  The alpha-
bungarotoxin was resuspended in coupling buffer consisting of 0.1 M NaHCO3 with 0.5 M NaCl 
(pH 8.3) and left to dissolve until addition to the beads.  Beads were reconstituted in 1 mM cold 
HCl for 1 h, changing every 15 min by removing the solution after letting the beads settle.  The 
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beads were then washed 3X with distilled water and 1X with coupling buffer, before the 
resuspended alpha-bungarotoxin prepared above, was added to the beads.  The bead-ligand 
solution was placed on rotation overnight at 4°C.  The next day the beads were washed 3X with 
coupling buffer and incubated in 0.2 M glycine (pH 8.0) at room temperature for 2 h.  The beads 
were washed in coupling buffer and then 0.1 M acetate buffer (pH 4.0) containing 0.5 M NaCl.  
This dual wash cycle was performed 4 times.  If the beads were not used immediately, they were 
stored in 1.0 M NaCl at 4°C. 
2.2.3 Western Blot 
Samples analyzed by western blot were boiled for 5 min after addition of Laemmli buffer and 
loaded into a 12.5% Tris-HCl polyacrylamide gel with Seeblue Plus 2 markers (Invitrogen).  The 
gel was run at 40 mAmps per gel until loading buffer ran out and transferred to nitrocellulose 
membranes overnight at 4°C and 150 mAmps.  The nitrocellulose was stained with Ponceau S 
solution and the appropriate strips for specific antibodies cut out and blocked in 2% milk in Tris-
Buffered Saline with Tween-20 (TBSt) for monoclonal antibodies or 2% milk, 1% BSA in TBSt 
solution for polyclonal antibodies.  The membrane was washed with TBSt and incubated 
overnight with the primary antibody at required dilution in TBSt.  The next day the blot was 
washed with TBSt and incubated with the secondary antibody in blocking solution.  The blot was 
washed again with TBSt and then developed using Supersignal West Pico or Femto solution 
(Pierce) and results captured on Kodak Blue X-Omat film.  Band densitometry analysis was 
performed using the Personal Densitometer SI (Molecular Dynamics). 
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2.2.4 Electromyography and Contractile Force Experiments 
Wildtype and caveolin-3 null mice were anesthetized by IP injection of urethane.  Upon 
anesthetization, the lower hind half and the ventral neck area of the animal was shaved.   A 
tracheotomy was performed using 90µm diameter tubing to ease animal breathing.  The Achilles 
tendon was exposed, tied to a force transducer, and cut proximal to the ankle.  The sciatic nerve 
to the adjacent leg was exposed with a small skin incision and by separating the covering muscle.  
The nerve was covered with mineral oil to maintain the conductivity of the nerve.  A stimulating 
electrode was placed under the nerve and the nerve cut proximal to the pelvis to remove reflex 
responses.  A recording electrode was placed into the gastrocnemius muscle through a small 
incision in the skin covering the gastrocnemius muscle.  The nerve was subsequently stimulated 
at various intensities and frequencies.  Simultaneous compound muscle action potentials 
(CMAP) recordings and muscle contractile force data were collected and analyzed using 
National Instruments program Labview 7.0.  If the animal maintained consistent breathing at the 
end of analyzing the first leg, the opposite Achilles tendon and sciatic nerve were prepared and 
EMG and muscle contraction experiments performed.  Statistical analysis was performed by 
Student’s T-test 
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3.0  ROLE OF CAVEOLIN-3 IN NACHR CLUSTERING 
3.1 INTRODUCTION 
While the localization of caveolin-3 and nAChR have been separately studied in muscle 
and myotubes, limited research on the co-localization and association of these proteins has been 
conducted.  Published research locates caveolin-3 and nAChR to the sarcolemma, though 
nAChR is highly localized and caveolin-3 is globally expressed at the sarcolemma.  Expression 
of caveolin-3 and nAChR is upregulated during myoblast differentiation.  Both proteins have 
been localized to the high lipid microdomains known as detergent resistant membranes by 
sucrose gradient fractionation experiments.  Co-localization and association of the dystrophin-
glycoprotein complex with caveolin-3 and nAChR each has been identified by 
immunofluorescence and immunoprecipitation, respectively (Song, Scherer et al. 1996; 
Marchand, Devillers-Thiery et al. 2002). 
The co-localization of caveolin-3 and the nAChR by alpha-bungarotoxin staining of 
single muscle fibers and muscle cross-sections was first described in rat muscle (Carlson, 
Carlson et al. 2003).  These experiments showed caveolin-3 and nAChR co-localization, with 
caveolin-3 extending beyond the nAChR staining.  This research also identified decreased co-
localization of caveolin-3 and the nAChR in aged rats. 
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Caveolin-3 and the nAChR have been briefly analyzed in other studies with differing 
conclusions.  Immunofluorescent staining of caveolin-3 and nAChR after agrin treatment for 12 
h does not show any co-localization at the membrane (Trinidad and Cohen 2004).  The authors 
suggest that nAChR and caveolin-3 co-localize internally upon removal of agrin, though no 
merged images identifying these conclusions were shown.  Many of these experiments were also 
performed several hours after live cell labeling for the nAChR with alpha-bungarotoxin, an 
irreversible inhibitor of nAChR.  Alpha-bungarotoxin binding of nAChR increases 
internalization and degradation of the receptor (Pumplin and Fambrough 1982).  The role of 
alpha-bungarotoxin in the internalization of the nAChR taken may explain the assertions and 
conclusions of Trinidad et al. (2004).  The internal co-localization of caveolin-3 and nAChR may 
be further explained as caveolin-3 has been shown to assist in the internalization of the insulin 
receptor after insulin activation, and this may be the role caveolin-3 is playing upon binding of 
the nAChR by the antagonist alpha-bungarotoxin (Fecchi, Volonte et al. 2006). 
Caveolins have been shown to localize to high cholesterol and sphingolipid membrane 
microdomains, and can be isolated from other cellular proteins by Triton-X-100 lysis and 
separated by discontinuous sucrose gradient fractionation (Lisanti, Scherer et al. 1994).  The high 
lipid containing particulate floats at the interface of layered 5% and 30% sucrose solutions, 
containing 2-5% of total cellular protein.  This process first described to separate caveolae, also 
separates out other non-caveolin associated lipid microdomains or lipid rafts, as proteins reside 
in the buoyant fraction in the absence of caveolin expression.  The nAChR and associated protein 
rapsyn were shown to co-localize to lipid raft fractions with endogenous caveolin-1 when 
heterologously expressed in immortalized African green monkey cells (Cos).  Each of these 
proteins is still localized to the lipid raft domain when expressed alone (Marchand, Devillers-
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Thiery et al. 2002).  Stetzkowski et al. found that nAChR localized in the lipid fraction of 
differentiated myotubes both with and without agrin stimulation (2006).  An additional study 
found that agrin treatment of C2C12 myotubes led to translocation of nAChR to the lipid raft 
domains as identified by sucrose gradient fractionation.  Immunofluorescent imaging showed 
that the nAChR co-localizes with lipid raft marker GM1 in both myotubes and diaphragm tissue 
(Zhu, Xiong et al. 2006).  The reagent, methyl beta cyclodextrin, is employed to deplete 
cholesterol from cell membranes.  Since lipid rafts and caveolae are cholesterol rich domains, 
this treatment disrupts the localization of proteins to detergent resistant membrane domains. 
Treatment of rapsyn expressing Cos cells with methyl beta cyclodextrin disrupted the punctate 
membrane localization of rapsyn in a concentration dependent manner (Marchand, Devillers-
Thiery et al. 2002).  Methyl beta cyclodextrin treatment of C2C12 myotubes disrupted the 
stability of nAChR clustering, decreased the nAChR half-life and removed caveolin-3 and 
nAChR from the buoyant fractions of sucrose gradients. (Zhu, Xiong et al. 2006)  Cholesterol 
depletion of C2C12 cells both before agrin treatment and after nAChR clustering attenuated 
cluster size.  In vivo methyl beta cyclodextrin treatment of prenatal mice decreased overall 
nAChR clustering in the diaphragm at birth (Stetzkowski-Marden, Gaus et al. 2006). 
While prior research touches on the potential of caveolin-3 associating with the nAChR 
or playing a role in nAChR clustering, no conclusive results have been determined.  We 
hypothesize that there is a caveolin-3 and nAChR association, and that lack of caveolin-3 
expression affects nAChR clustering and neuromuscular junction formation.  With wildtype and 
caveolin-3 null mice and derived myoblast cultures, we further explored caveolin-3 and nAChR 
co-localization and association. 
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3.2 RESULTS 
3.2.1 nAChR and Caveolin-3 Co-localize in Wildtype Mouse Muscle 
To assess the physiological relevance of nAChR and caveolin-3 association, 
immunofluorescent staining was performed on 22 month old gastrocnemius muscle cross-
sections from wildtype and caveolin-3 null mice.  LGMD-1C is a subtype of limb-girdle 
muscular dystrophy caused by mutations in the caveolin-3 gene.  By staining older mice, we 
hypothesized that phenotypic changes would be more pronounced, due to a generally more 
Figure 3. Caveolin-3 and nAChR Co-localize in Wildtype Mouse Muscle 
Quadriceps muscles were dissected from 22 month-old wildtype and caveolin-3 null mouse muscle, embedded in 
OCT, cross-sectioned, stained and imaged by confocal microscopy. Images representative of 3 or more experiments 
were stained for nAChR-alpha (green) and caveolin-3 (red) and co-localization is signified by yellow.  Figure was 
originally published in the journal, Molecular Biology of the Cell (MBC)(Hezel, de Groat et al. 2009). 
 30 
distinct movement disability phenotype.  In Figure 3, wildtype muscle staining shows caveolin-3 
located along the sarcolemma of the myofiber, while nAChR co-localized to a distinct portion of 
the sarcolemma.  The nAChR localization is consistent with the literature reporting one 
innervation per myofiber.  In contrast, staining of caveolin-3 null muscle cross-sections had 
diffuse nAChR expression along the sarcolemma (Figure 3).  The caveolin-3 null image is over-
exposed in order to identify the myofiber structure.  Figures 3a and 3b are flattened Z-stacks 
images of the nAChR clustering from wildtype and caveolin-3 null muscle cross-sections.  
Notice the high level of nAChR and caveolin-3 co-localization indicated by yellow in the 
wildtype sample (Figure 4A).  The caveolin-3 null image is very planar and longer, representing 
distinct changes from the wildtype image (Figure 4B).  
 
Figure 4. Flattened Z-Stack Images of Wildtype and Caveolin-3 Null Mouse Cross-Sections 
Flattened Z-stack images from,wildtype (A) and caveolin-3 null (B) mouse quadriceps muscle, embedded in OCT, 
cross-sectioned, and stained for nAChR-alpha (green) and caveolin-3 (red). Confocal microscopy images 
representative from 3 or more experiments.  Overlap is in yellow. 
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3.2.2 Caveolin-3 and nAChR Co-localization at the Wildtype Neuromuscular Junction 
Figures 3 and 4 identify co-localization of nAChR and caveolin-3, but there is no 
neuronal staining to confirm that this co-localization occurs at the neuromuscular junction. 
Confirmation of co-localization of nAChR and caveolin-3 was accomplished by triple 
fluorescent whole-mount staining of wildtype Extensor Digitorum Longus muscle.  The 
dissected muscle was incubated in an antibody for neuronal marker beta-tubulin 3, and caveolin-
3 followed by the appropriate secondary antibodies and with Alexa 647 labeled alpha-
bungarotoxin.  The muscle was mounted on a slide and analyzed by confocal imaging.  
Caveolin-3 in red and nAChR in blue co-localize in pink juxtaposed to the nerve terminal labeled 
in green (Figure 4).  This juxtaposition is more prominent in the flattened Z-stack image 
identified where the most of the nAChR co-localizes with caveolin-3 and one can see the nerve 
innervating the neuromuscular junction (Figure 5).  
 
Figure 5. Caveolin-3 and nAChR Co-localization at the Wildtype Neuromuscular Junction 
The extensor digitorum longus muscle was dissected from a wildtype mouse and stained for nAChR (blue), 
caveolin-3 (red), and the motor neuron with beta-tubulin-3 (green) and imaged using confocal microscopy.  In the 
merged images, nAChR and caveolin-3 co-localization is represented in pink.  Images are representative of 3 or 
more experiments.  Figure was originally published in MBC (Hezel, de Groat et al. 2009). 
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Figure 6. Flattened Z-stack of Neuromuscular Junction Staining in Wildtype Mouse Tissue 
The extensor digitorum longus muscle was dissected from a wildtype mouse and stained for nAChR (blue), 
caveolin-3 (red), and the motor neuron with beta-tubulin-3 (green).  Tissue was imaged using confocal microscopy 
and is representative of 3 or more experiments.  For this image a Z-stack was flattened.  Caveolin-3 and nAChR 
association is represented in pink.  Figure was originally published in MBC (Hezel, de Groat et al. 2009). 
3.2.3 Upregulation of Caveolin-3 and nAChR Expression during Myoblast Differentiation 
 The observations in mouse tissue are supportive of nAChR and caveolin-3 association 
and of an effect of caveolin-3 on nAChR clustering. The goal was to analyze caveolin-3 and 
nAChR expression during differentiation of our myoblast cultures.  Our myoblast cultures are 
derived from mouse muscle resulting from the immorto-mouse being crossed with either 
wildtype or caveolin-3 null mice.  Cells of the immorto-mouse lineage contain a temperature 
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sensitive gene, causing the cells to proliferate when grown at 33°C under treatment with 
interferon-gamma.  The cells stop dividing and start differentiating when placed at 37°C without 
interferon-gamma.  This system allows for initiating proliferative cell lines of tissue lineages 
which have low replicating power in primary culture.  
Caveolin-3 and nAChR protein expression are upregulated during myoblast 
differentiation into myotubes.  To confirm the upregulation time course of these proteins in our 
myoblast cultures, whole cell lysates were collected at 0, 12, 24, 48, and 96 h and the subsequent 
western blots were probed for nAChR and caveolin-3 protein expression (Figure 7).  The results 
of this time course indicate that nAChR is expressed beginning at 12 h in wildtype cells and 
increases through 96 h.  Caveolin-3 null cells express some nAChR during proliferation which 
increases during differentiation with more robust expression than in wildtype cells at 96 hours of 
differentiation.  Caveolin-3 is expressed after 48 hours and robustly at 96 hours in wildtype cells 
only.  The wildtype upregulation schedule of nAChR and caveolin-3 in our culture system is 
consistent with the literature (Capanni, Sabatelli et al. 2003; Macpherson, Cieslak et al. 2006). 
 
Figure 7. Upregulation of Caveolin-3 and nAChR Expression during Myoblast Differentiation 
Wildtype and caveolin-3 null mouse derived myoblasts were differentiated for 0, 12, 24, 48 and 96 h.  Cells were 
lysed and total protein content normalized.  Whole lysates were analyzed by western blot and probed with caveolin-
3 and nAChR-alpha antibodies to identify protein expression. Image is representative of 3 experiments. 
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3.2.4 Agrin induced Clustering of nAChR in Differentiated Wildtype Myotubes 
Nerve released agrin induces clustering of nAChR in muscle which can be recapitulated 
in vitro by recombinant neural agrin treatment of differentiated myotubes.  In wildtype muscle, 
there was co-localization of caveolin-3 and nAChR, does this occur in cells after agrin treatment.  
Wildtype myotubes differentiated for 7 days were treated with 10ng/ml agrin for 24 h.  The 
myotubes were fixed with paraformaldehyde and stained using antibodies against caveolin-3 and 
nAChR-alpha followed by fluorescent tagged secondary antibodies.  Confocal microscopy of the 
myotubes indicated nAChR clustering similar to that found in mouse muscle with discrete 
sarcolemma nAChR clustering (Figure 8).  This indicates that agrin treatment of cells can be 
used to induce nAChR clustering. 
 
Figure 8. Agrin induced Clustering of nAChR in Differentiated Wildtype Myotubes 
Wildtype myoblasts, grown on untreated coverslips, differentiated for 7 days and treated with agrin for 24 h.  
Myotubes were probed with nAChR (green) and caveolin-3 (red) antibodies and appropriate fluorescent secondary 
antibodies.  Confocal microscopy images are representative of 3 or more experiments.  Co-localization is indicated 
by yellow in the merged image.  Figure was originally published in MBC (Hezel, de Groat et al. 2009). 
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3.2.5 Agrin induced nAChR Clustering Disrupted in Caveolin-3 Null Myotubes 
As agrin treatment of wildtype myotubes led to nAChR clustering, we wanted to see if 
caveolin-3 played a role in nAChR clustering by comparing clustering in wildtype and caveolin-
3 null differentiated myotubes. Wildtype and caveolin-3 null myoblasts were differentiated for 7 
days, treated with agrin for 24 h, and probed for localization of caveolin-3 and nAChR. Agrin 
treated wildtype myotubes form more discrete clusters, while agrin treatment of caveolin-3 null 
myotubes induces diffuse nAChR sarcolemmal localization (Figure 9).  This indicates that agrin 
treatment of cells can be used to delineate the role of caveolin-3 in nAChR clustering and 
neuromuscular junction formation. 
Figure 9. Agrin induced nAChR Clustering Disrupted in Caveolin-3 Null Myotubes 
Wildtype and caveolin-3 null mouse derived myoblasts were differentiated for 7 days and treated with neural agrin 
(10ng/ml) for 24 h.  Cells were fixed, stained and imaged using confocal microscopy.  Representative figures of 3 or 
more experiments with nAChR-alpha in green, caveolin-3 in red and co-localization represented in yellow (arrows). 
Figure was originally published in MBC (Hezel, de Groat et al. 2009). 
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3.2.6 Quantification of Abrogated  nAChR Clustering in Caveolin-3 Null Myotubes 
The clustering differences were quantified by two analyses.  One analysis compared the length of 
the clusters between the agrin treated wildtype and caveolin-3 null cells and the other looked at 
the number of clusters per field. Agrin induced nAChR clusters in wildtype cells were 2/3rds the 
size of nAChR clusters in caveolin-3 null cells, indicating changes in clustering of the nAChR 
(Figure 10A).  Agrin induced clustering per field was normalized by comparing to intrinsic 
clustering of non-agrin treated wildtype and caveolin-3 null myotubes.  Agrin induced 60% less 
clusters in caveolin-3 null myotubes as compared to agrin treated wildtype cells (Figure10B).  
This quantification suggests that caveolin-3 plays a role in nAChR clustering and that lack of 
caveolin-3 expression attenuates nAChR clustering.  
Figure 10. Quantification of Abrogated nAChR Clustering in Caveolin-3 Null Myotubes 
Analysis of the (A) average length of nAChR clusters in agrin treated differentiated myotubes; and (B) the average 
number of clusters per field as quantified using confocal microscopy. (A) n=2 *p<0.0029 (B) n=3 *p<0.025.  Figure 
was originally published in MBC (Hezel, de Groat et al. 2009). 
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3.2.7 Caveolin-3 and nAChR Associate in Wildtype Mouse Muscle 
The immunofluorescent co-localization experiments show co-localization but have no 
bearing on whether the proteins actually associate due to the resolution limits of confocal 
microscopy.  Immunoprecipitation is a method to assess protein association.  In this method, 
antibodies are bound by their conserved regions to beads leaving the hyper-variable region 
exposed to bind the protein of interest. The bead-antibody complex is used to precipitate the 
antibody targeted protein with associated proteins.  The associated proteins are then separated 
from each other by SDS treatment and analyzed by western blotting.  Muscle tissue from 
wildtype and caveolin-3 null mice was homogenized and the nAChR immunoprecipitated using 
alpha-bungarotoxin bound Sepharose beads.  Figure 11 indicates that caveolin-3 is 
immunoprecipitated with nAChR in wildtype muscle homogenates.  While a large piece of 
muscle tissue was homogenized, total nAChR expression was undetectable.  This lack of nAChR 
detection stems from nAChR expression only being at the neuromuscular junction of each 
myofiber, which is only 0.1% of the total muscle surface area.  A reciprocal immunoprecipitation 
Figure 11. Caveolin-3 and nAChR Associate in Wildtype Mouse Muscle 
Wildtype quadriceps muscle was excised, homogenized and the nAChR immunoprecipitated using alpha-
bungarotoxin (α-Btx) bound beads or MDM2, an unrelated antibody, bound to Protein A Sepharose beads.  The 
immunoprecipitates were analyzed by western blot probed with nAChR and caveolin-3 antibodies. Images are 
representative of 3 or more experiments.  Figure was originally published in MBC (Hezel, de Groat et al. 2009). 
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using a caveolin-3 antibody was not successful.  This may result from the differential expression 
between the proteins with caveolin-3 being much more prevalent than the nAChR, possibly 
saturating the antibodies without enough bound nAChR for successful western blot detection. 
3.2.8 Agrin Induces Association of Caveolin-3 and nAChR in Wildtype Myotubes 
To finish validating that agrin treatment after myoblast differentiation mimics the nAChR 
organization process in mouse muscle, an immunoprecipitation of nAChR was performed on 
differentiated wildtype myotubes treated with and without agrin.  In agrin treated myotubes, as in 
muscle, caveolin-3 immunoprecipitated with the nAChR (Figure 12).  Interestingly, agrin 
treatment for 24 hours increased the association of these proteins.  While there was some 
association between caveolin-3 and nAChR in differentiated myotubes, agrin treatment increased 
the association of these proteins. 
 
Figure 12. Agrin Induces Association of Caveolin-3 and nAChR in Wildtype Myotubes 
Differentiated wildtype myotubes were treated with and without agrin for 24 h.  Myotubes were lysed, 
immunoprecipitations performed using a nAChR antibody, analyzed by western blot, and probed with nAChR and 
caveolin-3 antibodies. Figure is representative of 3 or more experiments. 
 39 
3.2.9 Agrin Induces Caveolin-3 Association with nAChR 20 Fold 
Since the above immunoprecipitations are descriptive, quantification of the association 
was warranted to better understand the binding dynamics of these proteins.  To this end, an 
immunoprecipitation in wildtype myotubes was performed using alpha-bungarotoxin bound 
Sepharose beads and analyzed by western blot. To better understand the relative amounts of 
protein immunoprecipitated to the total protein expression, the immunoprecipitates were 
analyzed with varying concentrations of total proteins by western blot to mimic the amount of 
protein immunoprecipitated (Figure 13).  The immunoprecipitated proteins and corresponding 
portion of   
Figure 13. Agrin Induces Caveolin-3 Association with nAChR 20 Fold 
Differentiated wildtype myotubes treated with or without agrin for 24 h.  Cells were lysed and nAChR pulled-down 
with alpha-bungarotoxin bound beads.  Analyzed by western blot and comparing the amount pulled down with total 
concentrations. Representative results from 2 experiments. Figure was originally published in MBC (Hezel, de Groat 
et al. 2009). 
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totals were then extrapolated to understand the total amount of protein association, a technique 
performed by Zhu et al. (2006).  As before, these experiments were carried out only by 
immunoprecipitating nAChR.  Again there was an increase in nAChR and caveolin-3 association 
upon agrin treatment.  Through comparison of immunoprecipitate with the concentrations of 
total protein there was a 20 fold increase in caveolin-3 and nAChR association. To understand 
this calculation, this western blot indicates that only 4% of the total nAChR expression was 
immunoprecipitated with the alpha-bungarotoxin bound beads in both the agrin treated and 
untreated samples.  The agrin untreated immunoprecipitates pulled down around 0.01% of total 
caveolin-3 expression, while the agrin treated immunoprecipitates appeared to be similar to 
about 0.2% of total caveolin-3 expression.  As only 4% of total nAChR was immunoprecipitated, 
a correction of 25 was applied to all calculations.  When 100% of the nAChR is 
immunoprecipitated 0.25% of total caveolin-3 is also pulled down in agrin untreated myotubes.  
While in the agrin treated myotubes 5% of the total caveolin-3 is immunoprecipitated with 
nAChR, yielding a 20 fold change.  This corresponds to the co-localization found in agrin treated 
myotubes where most of the nAChR co-localizes with caveolin-3.  Since caveolin-3 is expressed 
globally in the myotubes only a portion of caveolin-3 actually associates with nAChR.      
3.2.10  Caveolin-3 and nAChR  Associate at a Ratio of 14:1 after heterologous transfection 
The above nAChR and caveolin-3 association was quantified in differentiated cultured 
myotubes.  To further determine whether these proteins interact, several heterologous 
transfection experiments were performed.  Using nAChR subunit constructs kindly shared by Z. 
Z. Wang, nAChR and caveolin-3 were transfected into 3T3 cells.  Immunoprecipitation with 
alpha-bungarotoxin bound beads or a nAChR antibody immunoprecipitated caveolin-3 was 
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performed (data not shown).  Immunoprecipitation of caveolin-3 with the reconstituted nAChR 
occurred with both whole fetal and adult nAChR forms. 
Quantification of protein association by western blot is possible when using the same 
antibody for detection to eliminate the variability of antibody affinity.  This can be accomplished 
by transfecting DNA constructs coding similarly tagged proteins.  Thus, nAChR-alpha-myc 
subunit was cloned as outlined in the methods.  Our lab already had a myc-tagged caveolin-3.  
These myc-tagged caveolin-3 and nAChR-alpha constructs were co-transfected into 3T3 cells 
and a sequential immunoprecipitation was performed after 48 h (Figure 14).  A sequential 
immunoprecipitation is where two immunoprecipitations are performed one after another.  After 
48 h, the cells were lysed and a caveolin-3 immunoprecipitation performed.  The  
Figure 14. Caveolin-3 and nAChR Associate at a Ratio of 14:1 after Heterologous Transfection 
3T3 cells were heterologously transfected with myc tagged caveolin-3 and nAChR-alpha constructs.  48 h later the 
lysates were collected and a sequential immunoprecipitation performed and analyzed by western blot.  Densitometry 
analysis indicated a 14:1 ratio of caveolin-3 to nAChR-alpha.  Representative results from 3 experiments.  Figure 
was originally published in MBC (Hezel, de Groat et al. 2009). 
 42 
immunoprecipitated proteins were isolated from the beads and antibodies by addition of 0.5% 
SDS in lysis buffer and incubating the samples at 50°C for 10 m.  The protein solution was 
collected and diluted to 0.1% with lysis buffer and immunoprecipitation with a nAChR antibody 
was performed.  Again the proteins were isolated and collected from the beads and antibodies as 
before.  Lammeli buffer was added to the isolated proteins and analyzed by western blot and 
probing with a c-myc antibody.  Band analysis by densitometry indicated that there were 
approximately 14 times more caveolin-3 bound to the nAChR-alpha subunit (Figure 14).  As 
caveolae consist of 14-16 caveolin-3 proteins bound together, this suggests one nAChR-alpha 
subunit per caveolae.  This may indicate that caveolae function as a platform for nAChR 
signaling and protein associations. 
3.3 DISCUSSION 
While other research has touched on the possibility of caveolin-3 association with 
nAChR, this research provides definitive answers by using tools well suited for this task.  
Caveolin-3 co-localizes and associates with nAChR in muscle and in agrin treated differentiated 
myotubes.  Lack of caveolin-3 appears to change the attributes of the nAChR clustering in 
caveolin-3 null muscle and differentiated myotubes.  This research suggests that caveolin-3 is 
important in nAChR clustering and that nAChR-alpha subunits and caveolin-3 associate. 
There are distinct differences in nAChR and caveolin-3 co-localization from muscle to 
differentiated myotubes in culture.  The co-localization appears much stronger in the muscle as 
compared to our culture model.  This could result from the cell culture model not containing the 
whole complement of signals for neuromuscular junction formation.  Since these experiments 
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were performed using only muscle cells treated with a soluble form of agrin and without the 
associated nerve cells, it is most likely that post-synaptic junction formation is not as robust or 
directed in vitro as in vivo.  In muscle, the synaptic localization of the nucleus induces increased 
transcription and translation of the nAChR and associated proteins, leading to higher expression.  
Various other differences between muscle and cultured myotubes could also affect association.  
For example, agrin is anchored to the extra cellular matrix after neuronal release in vivo though 
in culture a soluble agrin form is used.  Research has shown that agrin bound to substrate can 
induce clustering even without MuSK kinase activation (Bromann, Zhou et al. 2004).  The lack 
of interplay between the nerve and muscle is also thought to play a role, as ACh release has been 
shown to disperse clusters not fully anchored at the membrane (Madhavan, Zhao et al. 2003).  
The lack of nerve induced contraction in the cell culture also may play a role in the maturation of 
the muscle neuromuscular junction which is not found in cell culture. 
The immunofluorescent staining of agrin induced differentiated wildtype and caveolin-3 
null myotubes indicates more diffuse nAChR localization in the caveolin-3 lacking myotubes.  
The caveolin-3 null myotubes form some clusters but not as distinctly as wildtype myotubes 
suggesting an inability to carry out the full clustering signal pathway.  This is further confirmed 
by the decreased number of clusters per view in the agrin treated null myotubes.  As with the 
differentiated myotube co-localization above, this model system does not contain all signaling 
mechanisms found in the in vivo muscle system.  It must also be considered that caveolin-3 null 
mice are viable but live slightly shortened lives, suggesting that while the neuromuscular 
junction formation is impaired, it definitely is not dysfunctional. 
The analysis of caveolin-3 and nAChR-alpha protein association in cultured myotubes 
was difficult due to uneven protein expression, with caveolin-3 being more prevalent than the 
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nAChR-alpha subunit.  Our immunofluorescence data indicate nAChR and caveolin-3 localize to 
the plasma membrane, while the immunoprecipitation experiments reflect whole cell protein 
expression.  Immunoprecipitation using biotin bound alpha-bungarotoxin applied to the cell 
culture media and subsequent streptavidin immunoprecipitation might yield higher association 
results by isolating only the nAChR located at the membrane.  It has been suggested that only 
30% of the full nAChR is trafficked to the membrane, and so whole cell nAChR 
immunoprecipitation may skew the results (Wanamaker, Christianson et al. 2003).  Caveolin-3 to 
nAChR ratios are estimated from myotubes treated with agrin for 24 h. This does not take into 
account the affinity of the antibodies that were used to probe for each protein and the length of 
time ECL was incubated on the membrane before developing. 
Immunofluorescence and immunoprecipitation experiments indicate similar interactions 
between caveolin-3 and nAChR with only a portion of caveolin-3 co-localizing and associating 
with nAChR.   As noted before the immunoprecipitation experiments using whole lysates do not 
differentiate between cytoplasmic and membrane localized protein.  If these proteins only 
associate in one part of the cell and have other non-associating protein pools it may skew the 
association ratio calculation.  Another way to further confirm the ratio of nAChR and caveolin-3 
association in heterologously transfected cells would be through Forster energy resonance 
transfer.  This technique uses co-transfection of differentially labeled fluorescent proteins, where 
excitation of the chromophore on one protein induces a fluorescent emittance which 
consequentially activates the fluorophore on the associated protein.  The proximity of the 
fluorophores on the proteins cannot be farther than 10nm apart to use this technique.   This 
imaging experiment would further confirm protein association, while eliminating the possibility 
of data skewing due to differential protein localization.           
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Sequential immunoprecipitation of caveolin-3 followed by immunoprecipitation of the 
nAChR-alpha subunit indicated a 1:14 ratio of caveolin-3 to nAChR, fitting well in the role of 
each nAChR alpha-subunit interacting with a full caveolae.  These results do have some pitfalls.  
The sequential immunoprecipitation may have artifacts resulting from the use of SDS to remove 
the bound proteins from the antibody and bead complex.   This treatment could potentially 
remove the antibody from the beads, carrying over to the second immunoprecipitation skewing 
the data.  As caveolin-3 proteins form large structures by binding one another, the caveolin-3 
pulled-down but not bound to nAChR in the first immunoprecipitation may bind caveolin-3 
molecules already bound to nAChR, skewing the ratio results from the second 
immunoprecipitation.  In both the fetal and adult nAChR, there are 2 nAChR-alpha subunits in 
the full structure.  The sequential immunoprecipitation results suggest that only one nAChR-
alpha subunit must associate with a caveolae, this may be different with the all the nAChR 
subunits expressed.  
Our results indicate an association between caveolin-3 and nAChR.   More importantly, 
there are differences in the formation of nAChR clusters in caveolin-3 null and wildtype animals 
and derived agrin-treated differentiated myotubes.  Whether these changes actually affect 
neuromuscular junction function or not remains to be seen.  The role caveolin-3 plays in the 
signaling cascade leading to nAChR clustering needs to be delineated to identify how caveolin-3 
changes the nAChR localization and neuromuscular junction as shown above. 
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4.0  CAVEOLIN-3 ROLE AT THE MOLECULAR LEVEL IN NACHR CLUSTERING 
4.1 INTRODUCTION 
The neuromuscular junction undergoes many changes in producing a highly efficient 
signaling synapse.  The muscle without input from the nerve produces nAChR clusters along the 
midline of differentiated myofibers (Lin, Burgess et al. 2001).  During muscle innervation by the 
motorneuron, these clusters are modified by neuronal agrin release, inducing nAChR cluster 
translocation to juxtaposition with the nerve terminal.  The synapse then undergoes further 
structural modifications to enhance the efficiency of synaptic transmission (Wiesner and Fuhrer 
2006). 
For many years experiments were performed to identify proteins that induce clustering of 
the nAChR.  While laminin, neuregulin, fibroblast growth factor (FGF), midkine and 
acetylcholine were probed for nAChR clustering ability, agrin has been determined as the most 
potent nAChR clustering inducing ligand (Sanes and Lichtman 2001).  Agrin is produced and 
released in different forms by both the nerve and muscle.  The muscle form has no nAChR 
clustering activity.  Neural agrin is different from muscle agrin in that it contains 2 inserted 
amino acid sequences.   These inserts confer activity to agrin, which can be used in vitro to 
stimulate nAChR clustering in differentiated myotubes (Ferns, Campanelli et al. 1993). 
Since the Torpedo electric organ is a modified neuromuscular junction expressing the 
nicotinic acetylcholine receptor, it has served as a model for determining important protein 
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associations and signals.  Many of the essential proteins found to bind the nAChR, or those that, 
due to proximity, are otherwise involved in nAChR clustering result from studying this model 
system.  These proteins include MuSK, which is involved in the initiation of clustering signaling 
and Rapsyn, an important binding protein of nAChR.  These proteins have formed the basis for 
clustering research.  Both, MuSK and Rapsyn null mice die at birth, due to dysfunctional 
diaphragm neuromuscular junctions leading to asphyxiation of the pups (Gautam, DeChiara et al. 
1999). 
The signaling pathway initiated by agrin acting on proteins in the sarcolemma and 
leading to nAChR clustering has been extensively studied.  The sequence of these protein 
associations and their role in signaling is currently unknown.  Many proteins have been 
identified as being involved in nAChR organization though the order of their associations and 
path of signal transduction has not been clarified (Figure 11).  Since many of these proteins have 
been identified as binding MuSK, or Rapsyn, it is not known whether these proteins are involved 
with primary clustering signaling or signaling induced by agrin treatment but not directly 
affecting clustering. 
Until recently, MuSK had been considered the protein initiating nAChR clustering 
pathway.  This receptor tyrosine kinase is activated by agrin treatment inducing auto-
phosphorylation and a subsequent signaling cascade.  Due to a lack of direct agrin association, it 
was long hypothesized that MuSK activation requires an associated protein for signaling 
nicknamed muscle associated signaling complex (MASC) (Glass, Bowen et al. 1996).  MASC 
was recently identified to be LDL receptor related protein 4 (LRP4), which is also essential for 
neuromuscular junction formation and animal survival upon birth (Kim, Stiegler et al. 2008; 
Zhang, Luo et al. 2008). 
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Figure 15. Model of Protein Signaling Relevant to nAChR Clustering 
The pathway for nAChR clustering has not been fully elucidated.  The pathway is initiated by neural agrin binding 
to LRP4 and inducing MuSK phosphorylation leading to eventual localization of Rapsyn (Rpsn) and the nAChR 
(blue barrels around rapsyn) at the neuromuscular junction.  Agrin, LRP4, MuSK, Rapsyn and nAChR subunits are 
all essential proteins and removal of any of these proteins results in animals that die at birth.  Research has focused 
on proteins that, after agrin activation, bind MuSK (Tid1, Dok-7, Dsh-1, Abl, GGT, src, 14-3-3) and Rapsyn (APC 
and JNK). How these proteins fit into a nAChR cluster inducing pathway is still undetermined.  Likewise Rac1, Rho 
and Pak1 are essential but how agrin leads to activation and transmission of their activation is not clear. Solid arrows 
are identified associations while the dashed arrows are implied signaling processes.  
Since the discovery of MuSK, much research has focused on identification of proteins 
bound to and activated by MuSK after agrin treatment.  Proteins found to bind MuSK and be 
activated by agrin treatment are the src family kinases, geranyl geranyl transferase I, dishevelled, 
abl, Doc-7, 14-3-3 and recently identified TID1 (Mohamed, Rivas-Plata et al. 2001; Luo, Wang 
et al. 2002; Luo, Je et al. 2003; Strochlic, Cartaud et al. 2004; Okada, Inoue et al. 2006; Linnoila, 
Wang et al. 2008).   Many of these proteins have been shown to be essential in clustering through 
knockdown by interference RNA or by signal abrogation by protein specific inhibitors.  Whether 
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and how these proteins fit into the nAChR clustering signaling scheme or structure is not fully 
understood.  
Rapsyn has been found to be at a 1:1 stoichiometry with nAChR in myotubes 
(LaRochelle and Froehner 1986; Hughes, Kusner et al. 2006).  Originally discovered in the 
electric organ of the electric eel, co-expression of rapsyn and nAChR is required for nAChR 
clustering (Sealock, Wray et al. 1984).  By also binding beta-dystroglycan in the dystrophin 
glycoprotein complex, rapsyn is involved in the stabilization of the nAChR clusters (Dobbins, 
Zhang et al. 2006).  Laminin, which is a weak alternative signaling pathway for nAChR 
clustering, also signals through rapsyn (Banks, Fuhrer et al. 2003).  Simultaneous expression of 
rapsyn with src family kinases leads to nAChR subunit phosphorylation (Banks, Fuhrer et al. 
2003). 
Other proteins identified as essential for nAChR clustering include the small GTPases, 
Rac1 and Rho, and other signaling proteins Pak1 and APC. (Weston, Yee et al. 2000; Wang, Jing 
et al. 2003; Weston, Gordon et al. 2003; Weston, Teressa et al. 2007)  Most likely these signaling 
proteins fall between MuSK activation and nAChR clustering though their position in the 
clustering pathway has not been determined. 
Since our results show association and co-localization of caveolin-3 and nAChR and 
suggest modified clustering in caveolin-3 knockout mice and differentiated myotubes (Chapter 
3), the next step was to look at whether caveolin-3 played a role in the signaling cascade of 
nAChR clustering.  As the distinct pathway is not yet defined, this research focused on proteins 
essential in nAChR clustering. 
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4.2 RESULTS 
4.2.1 Agrin induced Rac1 activation in Wildtype Myotubes 
To understand the abrogation of clustering in the caveolin-3 null myotubes, proteins 
identified in nAChR clustering were compared to those that associate with the caveolin family.  
Rac1 was a strong candidate, as it is essential to nAChR clustering and requires binding to 
caveolin-1 for successful signaling in vascular endothelial cells (Zuo, Ushio-Fukai et al. 2005).  
Rac1 is a small GTP binding protein involved in cell mediated cytoskeletal reorganization, cell 
growth and kinase activation pathways.  Rac1 has been shown to be an essential intermediary in 
nAChR clustering, which is abrogated after expression of dominant negative Rac1 (Weston, Yee 
et al. 2000).  Rac1 localized to the cytoplasm, translocates with caveolin-1 to the plasma 
membrane after angiotension II treatment of vascular smooth muscle cells (Zuo, Ushio-Fukai et 
al. 2005).  Several papers show that knockdown of caveolin-1in vascular endothelial cells 
disrupts Rac1 activation and the eventual signaling endpoint (Cho, Ryu et al. 2004; Zuo, Ushio-
Fukai et al. 2005; Hu, Ye et al. 2008; Singleton, Chatchavalvanich et al. 2009).  Due to 85% 
similarity between caveolin-1 and caveolin-3, it is likely that both proteins have similar 
interactions with Rac1.  Rac1 may be the link that is disrupted in caveolin-3 null myotubes 
during nAChR clustering.   
To determine whether lack of caveolin-3 affects agrin induced Rac1 activation, Rac1 activation 
was assessed over an agrin treatment time course in wildtype and caveolin-3 null myotubes.   
Agrin treatment induces activation of Rac1, and Cdc42 (Weston, Yee et al. 2000). Activated 
Rac1 can be isolated and assessed through pulling down the binding domain of p21 activated 
kinase 1 (Pak1) to which activated Rac1 binds (Weston, Yee et al. 2000).  Using a fused GST-
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Pak1 binding domain (PBD) construct from Dr. Daniel Altschuler’s laboratory, a GST-PBD 
fusion protein was produced and bound to glutathione-bound agarose beads. Activation of Rac1 
was analyzed in wildtype and caveolin-3 null myotubes treated with 10ng agrin per ml of agrin 
for 0, 15, 60 or 240 min.  In wildtype myotubes, activated Rac1 peaked after 1 h of agrin 
treatment, while caveolin-3 null myotubes maintained basal expression of activated Rac1 without 
any agrin induced activation (Figure 16).  The lack of Rac1 activation corresponds to the 
differences in nAChR clustering seen in caveolin-3 null myotubes. 
Figure 16. Agrin induced Rac1 Activation in Wildtype Myotubes 
Wildtype and caveolin-3 null mouse derived myoblasts were differentiated for 7 days and treated with agrin for 0, 
15, 60 and 240 min.  Cells were lysed and activated Rac1 was pulled down using a glutathione S-transferase-Pak1 
binding domain fusion protein bound to glutathione sepharose beads.  Western blot analysis probed with Rac1 
antibody indicated activated Rac1.  Total expression of Rac1 in lysates is located below.  Representative results 
from 3 or more experiments.  Figure was originally published in MBC (Hezel, de Groat et al. 2009). 
4.2.2 Agrin induces Caveolin-3 and Rac1 Association 
Our previous data indicate that Rac1 is not activated in agrin treated caveolin-3 null 
myotubes in contrast to the activation in wildtype cells.  Whether this occurs due to lack of 
caveolin-3 binding is not known, but probably due to the effect of caveolin-1 on Rac1 activation.  
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Immunoprecipitation of caveolin-3 in agrin treated myotubes was performed to identify whether 
caveolin-3 interacts with Rac1.  Figure 17 shows that agrin induces the association of caveolin-3 
and Rac1 with the association peaking at a 15 min but remaining elevated at 4 h.  These data 
directly support the requirement of caveolin-3 for Rac1 activation and nAChR clustering. 
Figure 17. Agrin induces Caveolin-3 and Rac1 Association 
Wildtype and caveolin-3 null mouse derived myoblasts were differentiated for 7 days and treated with agrin for 0, 
15, 60 and 240 min.  Cells were lysed and caveolin-3 pulled down using caveolin-3 antibody and Protein A 
Sepharose beads.  Western blot analysis probed with Rac1 antibody indicated association.  Total expression of Rac1 
and caveolin-3 is located below. n=3. Figure was originally published in MBC (Hezel, de Groat et al. 2009). 
4.2.3 What activates Rac1 
Rac1, as a small G-protein is activated by the exchange of bound GDP for GTP.  This 
exchange is catalyzed by Guanine nucleotide exchange factors (GEFs).  There are a large 
number of proteins that act as GEFs, and due to their transient interaction with the G-proteins, it 
is difficult to determine which GEF is involved with activation.  Immunoprecipitations for Rac1 
and associated GEFs were performed in an attempt to identify the GEF responsible for agrin 
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induced Rac1 activation in myotubes.  Sos-1, the first GEF identified also called son of 
sevenless, has been shown to activate Rac1 in response to angiotension II in vascular smooth 
muscle cells (Zuo, Ushio-Fukai et al. 2005).  Caveolin-3 binding to Sos-1 was identified but 
Rac1 association with Sos-1 was elusive (Data not shown).  Geft is a muscle specific GEF 
protein that has been identified to activate Ras family proteins (Bryan, Mitchell et al. 2005).  
Association between GEFT and Rac1 was also not observed (Data not shown). 
4.2.4 Agrin induced JNK Activation is not Affected in Caveolin-3 Null Myotubes 
JNK activation is required for expression of the epsilon subunit of nAChR (Si, Wang et 
al. 1999).  JNK phosphorylation results from activated Rac1 and Cdc42 expression, and this 
phosphorylation is abrogated by expression of Rac1 and Cdc42 kinase null constructs (Weston, 
Yee et al. 2000).  Due to the implication that JNK phosphorylation occurs after Rac1 activation, 
JNK activation was assessed in whole cell lysates over an agrin treatment time course of 0, 15, 
60, and 240 min.  Lysates were analyzed by western blots probed for phospho-JNK.  There was 
JNK activation at 15 min in both wildtype and caveolin-3 null myotubes treated with agrin 
(Figure 18).  These results show activation which does not follow the time course of agrin  
Figure 18. Agrin induced JNK Activation is not Affected in Caveolin-3 Null Myotubes 
Wildtype and caveolin-3 null mouse derived myoblasts were differentiated for 7 days and treated with agrin for 0, 
15, 60 and 240 min.  Cells were lysed, and protein content normalized.  Western blot analysis of total lysate was 
probed with a phospho-JNK antibody. n=2.  Figure was originally published in MBC (Hezel, de Groat et al. 2009). 
 54 
 
activation of Rac1, implying that agrin induced JNK activation occurs through a different 
pathway.  
4.2.5 Caveolin-3 is important for MuSK Phosphorylation 
Results presented earlier (Figure12), found abrogation of nAChR clustering signaling at 
the point of Rac1 activation.  Rac1 activation is recognized as an intermediate step in nAChR 
clustering.  Since subsequent experiments were unable to delineate whether signal abrogation 
occurred at Rac1 activation through localization of GEFs for Rac1, we focused on upstream 
signaling important for nAChR clustering.  MuSK, the protein located at the beginning of 
signaling cascade, was an appropriate starting point. 
MuSK has long been determined to be part of a protein complex involved in the initiation 
of clustering signaling.  MuSK is a receptor tyrosine kinase, whose kinase domain consists of 
most of the cytoplasmic domain and contains 6 tyrosines which have been shown to be 
phosphorylated upon agrin induced activation (Watty, Neubauer et al. 2000).  While there is no 
direct interaction between agrin and MuSK, agrin treatment induces MuSK autophosphorylation 
initiating the nAChR clustering pathway.  Analysis of agrin induced MuSK phosphorylation in 
myotubes was the next logical step.  Wildtype and caveolin-3 differentiated myotubes were 
treated with agrin for 0, 15, 60 or 240 min.  The cells were lysed and MuSK immunoprecipitated 
using a combination of polyclonal MuSK antibodies.  The samples were analyzed on a western 
blot and probed with a phospho-tyrosine antibody.  There was a peak in MuSK phosphorylation 
after 1 h of agrin treatment in both wildtype and caveolin-3 null cells, but the MuSK activation 
was stronger in the wildtype as compared to the caveolin-3 null myotubes (Figure 19).  The 
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caveolin-3 null myotubes had less MuSK overall than the wildtype myotubes, as found in 
analysis of total lysates.  Density analysis of the western blot results, indicate that overall MuSK 
expression was decreased by 1/3, while phosphorylation decreased 3/5 between wildtype and 
caveolin-3 null myotubes.  This suggests that loss of caveolin-3 results in not only decreased 
MuSK expression or stability but also changes in the level of MuSK activation. 
Figure 19. Caveolin-3 is important for MuSK Activation 
Wildtype and caveolin-3 null mouse derived myoblasts were differentiated for 7 days and treated with agrin for 0, 
15, 60 and 240 min.  Cells were lysed and MuSK pulled down using MuSK antibody bound to Protein A Sepharose 
beads.  Western blot analysis probed with a phospho-tyrosine antibody indicates MuSK activation.  Total expression 
of MuSK in lysates is located below.  Representative results of 3 or more experiments. Figure was originally 
published in MBC (Hezel, de Groat et al. 2009). 
4.2.6 Agrin induces MuSK and Caveolin-3 Association in Differentiated Myotubes 
Our research shows distinct differences in agrin activation of MuSK and overall MuSK 
expression between wildtype and Caveolin-3 null myotubes, suggesting that Caveolin-3 is 
important in the stability of MuSK.  The next step was to assess whether caveolin-3 and MuSK 
interact.  Using differentiated myotubes treated with 10ng/ml agrin for 0, 15, 60, and 240 min, 
MuSK was immunoprecipitated as before.  Western blot analysis of associated proteins was 
probed with an anti-caveolin-3 antibody.  The results indicated a basal level of caveolin-3 and 
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MuSK association with peaks after 1 h of agrin treatment in wildtype myotubes (Figure 20).  
This peak matches the peak activation of Rac1 found earlier and the peak in MuSK 
phosphorylation.  Overall MuSK expression was again decreased in the caveolin-3 null cells. 
Figure 20. Agrin induces MuSK and Caveolin-3 Association in Differentiated Myotubes 
Wildtype and caveolin-3 null mouse derived myoblasts were differentiated for 7 days, and treated with agrin for 0, 
15, 60 and 240 min.  Cells were lysed and MuSK was pulled down using MuSK antibody and Protein A Sepharose 
beads.  Western blot analysis probed with caveolin-3 antibody indicated association.  Total expression of MuSK and 
caveolin-3 in lysates is located below. Representative results of 3 or more experiments.  Figure was originally 
published in MBC (Hezel, de Groat et al. 2009).  
4.2.7 MuSK binds Caveolin-3 at the MuSK Caveolin Binding Domain 
The MuSK immunoprecipitation indicated association of MuSK with caveolin-3, but did 
not confirm that this interaction is direct.  There is the possibility of an adapter protein binding to 
both of them, which is not discriminated from actual protein-protein binding by 
immunoprecipitation.  The amino acid sequence of MuSK contains 2 putative caveolin-3 binding 
domains (CBD) consisting of the sequence OXOXXXXO, where Os are aromatic residues and 
Xs are other amino acids (Figure 21).  These binding domains, located in the kinase domain, 
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contain similar sequences to the sequences first identified as caveolin binding domains (Couet, 
Li et al. 1997).  The tyrosine residues contained in the caveolin-3 binding domains are not 
phosphorylated in MuSK activation (Watty, Neubauer et al. 2000). 
Figure 21. Diagram of MuSK Protein 
This diagram characterizes the known functional domains of the MuSK protein.  The tyrosines shown in the 
cytoplasmic domain represent tyrosines phosphorylated after agrin activation.  There are 2 caveolin-binding 
domains (CBD) within the kinase domain.  The important aromatic residues highlighted in red, are mutated in our 
Mutant A  (MutA) and Mutant B (MutB) constructs. Figure was originally published in MBC (Hezel, de Groat et al. 
2009). 
To further determine whether caveolin-3 and MuSK directly bind each other at the MuSK 
CBD, MuSK was cloned into an hemaglutinin (HA) tagged constitutively expressed vector.  
Using internal primers, PCR directed mutagenesis to alanine residues was performed on each of 
the caveolin binding domains.  The mutated MuSK sequences were cloned into the same vector 
as the wildtype MuSK sequence.  To understand caveolin-3 and MuSK binding, each MuSK 
vector in conjunction with a wildtype caveolin-3 vector were transfected into Ras transformed 
3T3 fibroblasts.  The overexpression of Ras suppresses endogenous caveolin-1 expression, 
removing the chance of caveolin-1 contamination.  Two days after transfection, the cells were 
lysed and immunoprecipitation with caveolin-3 antibodies performed.  MuSK binding to 
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caveolin-3 was analyzed by western blot and probed for the HA tag (Figure 22).  While there 
was strong affinity between caveolin-3 and wildtype MuSK, caveolin-3 binding to  MuSK with 
mutated caveolin binding domain A, was highly reduced and binding between caveolin-3 and 
MuSK caveolin binding domain B was not detected by western blotting. These results support a 
direct interaction between caveolin-3 and MuSK which requires the MuSK caveolin binding 
domains. 
Figure 22. Caveolin-3 binds MuSK at the MuSK Caveolin Binding Domains 
Ras cells were transfected with caveolin-3 and empty HA, HA-MuSK-WT, HA-MuSK-MutA, or HA-MuSK-MutB 
vectors.  48 h later, cells were lysed and caveolin-3 pulled down using a caveolin-3 antibody with Protein A 
Sepharose beads.  Western blot analysis probed with an HA antibody indicated association.  Total expression for HA 
and caveolin-3 in lysates is located below.  Figure is representative of 3 experiments.  Figure was originally 
published in MBC (Hezel, de Groat et al. 2009). 
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4.2.8 MuSK consistently Associates with Dishevelled-1 
The role that lack of caveolin-3 expression plays on proteins associated with MuSK 
remains to be tested.  Dishevelled-1 has been identified as a MuSK binding protein essential to 
nAChR clustering (Luo, Wang et al. 2002).  Disruption of dishevelled-1 expression through 
expression of a dominant negative construct disrupts spontaneous currents and attenuates agrin 
induced clustering but not intrinsic clustering.  Dishevelled-1 was found to co-immunoprecipitate 
with MuSK which is unchanged by agrin treatment (Luo, Wang et al. 2002).  Our results are 
consistent with those published by Luo et al. which show continuous association between MuSK 
and dishevelled-1 regardless of agrin treatment (Figure 23)(2002).  Lack of caveolin-3 does not 
influence MuSK and dishevelled-1 association. 
 
Figure 23. MuSK consistently Associates with Dishevelled-1 
Wildtype and caveolin-3 null mouse derived myoblasts were differentiated for 7 days and treated with agrin for 0, 
15, 60 and 240 min.  Cells were lysed and MuSK pulled down using a MuSK antibody and Protein A Sepharose 
beads.  Western blot analysis probed with dishevelled-1 (Dsh-1) antibody indicated association.  Total expression of 
MuSK and dishevelled-1 found in whole lysates is located below.  Figure is representative of 3 or more experiments. 
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4.2.9 Agrin induces Caveolin-3 Association with Dishevelled-1 
Analysis of dishevelled-1 association with caveolin-3 by immunoprecipitation after 
differentiated myotube treatment with agrin, showed that caveolin-3 and dishevelled-1 
association peaks 15 min after agrin treatment and remains elevated at 1h (Figure 24).  This time 
course corresponds with agrin-induced MuSK activation and MuSK and caveolin-3 association 
suggesting a signaling complex. 
 
Figure 24. Agrin induces Caveolin-3 Association with Dishevelled-1 
Wildtype and caveolin-3 null mouse derived myoblasts were differentiated for 7 days and treated with agrin for 0, 
15, 60 and 240 min.  Cells were lysed and dishevelled-1 (Dsh-1) pulled down using a dishevelled-1 antibody and 
Protein A Sepharose beads.  Western blot analysis probed with caveolin-3 (Cav-3) antibody indicated association.  
Total expression of dishevelled-1 and caveolin-3 in whole lysates is located below.  Figure is representative of 3 
experiments.  
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4.3 DISCUSSION 
This chapter addresses the role of caveolin-3 in the signaling cascade culminating in 
nAChR clustering.  This research, while attempting to be comprehensive, is hindered by the lack 
of a fully defined signaling pathway for nAChR clustering.  Lack of caveolin-3 expression 
disrupts activation of several proteins involved with signaling for nAChR clustering.  There is 
highly reduced Rac1 and MuSK activation in agrin treated caveolin-3 null myotubes.  The 
caveolin-3 null cells also have reduced overall MuSK expression.  The MuSK and caveolin-3 
interaction is direct and can be abrogated through directed mutagenesis of the caveolin binding 
domains on MuSK.  Interestingly, MuSK binding to its partner dishevelled-1 is unchanged. 
While limited agrin induced Rac1 activation in the caveolin-3 null myotubes is observed, 
there is still some Rac1 activation.  This activation may result from alternate pathways which 
signal through Rac1.  Induction of Rac1 activation has been shown to occur upon agrin treatment 
and the pathway converges with laminin activation (Weston, Teressa et al. 2007).  Rac1 is also 
implicated in cytoskeletal organization and may reflect a basal level of cytoskeletal 
reorganization in some cells.  Since our myotube cultures still contain undifferentiated 
myoblasts, it is possible that these cells contain Rac1 activation.  Rac1 activation is induced by 
mechanical stretch, though this is unlikely to be the cause, as there were contractions occurring 
in both differentiated myotube cultures and all cultures were treated similarly (Kawamura, 
Miyamoto et al. 2003). 
Rac1 and Rho are activated sequentially for successful cluster formation.  Myoblast 
transfection with constitutively active Rac1 and Rho constructs, induces nAChR clustering with 
normal characteristics (Weston, Gordon et al. 2003).  Abrogation of either Rac1 or Rho by 
expression of dominant negative constructs, disrupts clustering of the nAChR.  Attempts to look 
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at Rho activation in wildtype and caveolin-3 null myotubes were unsuccessful, but most likely 
mirror the Rac1 activation results, since Rac1 signaling is upstream of Rho (Weston, Gordon et 
al. 2003). 
The similar activation profile of JNK in both wildtype and caveolin-3 null cells, does not 
correspond to the requirement of Rac1 activation ahead of JNK activation as put forth by Weston 
et al. (2000).  These findings were refuted by Luo et al. (2002) which showed that expression of 
dominant negative JNK does not affect intrinsic or agrin induced clustering.  This research also 
found that Pak1 can be activated through MuSK and dishevelled-1 independently of Rac1 (Luo, 
Wang et al. 2002).  Additionally, JNK can be activated through a neuregulin activated ErbB2 
pathway predominantly upregulated in cell culture, occurring at the same levels induced by 
simultaneous agrin and neuregulin treatment (Si, Wang et al. 1999; Lacazette, Le Calvez et al. 
2003).  JNK activation may not be as important in nAChR clustering as first identified.  
However, it still may be required for nAChR-epsilon subunit phosphorylation, though the 
activation shown here does not occur through Rac1 (Si, Wang et al. 1999).      
MuSK was considered the known step in agrin induced signaling of nAChR clustering.  
There was a theoretical, but unidentified protein postulated to bind agrin and assist in the signal 
transduction through MuSK (Glass, Bowen et al. 1996).  This protein, originally called the 
muscle accessory specificity component (MASC), has been recently identified as LDL receptor 
related protein 4 (LRP4).  This protein was identified as mutated in polysyndactyly which is a 
condition of webbed fingers and toes and implicated in other development dysfunctions (Simon-
Chazottes, Tutois et al. 2006).  By an N-ethyl-N-nitrosourea mutagenesis mouse screen, LRP4 
was identified as essential for neuromuscular junction formation in which mutated mice die at 
birth (Weatherbee, Anderson et al. 2006).  Myotubes derived from myoblasts of LRP4 mutant 
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embryonic mice do not respond to agrin treatment implicating this gene in clustering 
(Weatherbee, Anderson et al. 2006).  Subsequent research found that LRP4 binds agrin and 
MuSK and is phosphorylated identifying LRP4 as the theoretical MASC in nAChR clustering 
signaling (Kim, Stiegler et al. 2008; Zhang, Luo et al. 2008). Additionally, the expression of 
MuSK and LRP4 follow the same pattern during differentiation (Zhang, Luo et al. 2008). 
Our research focuses on MuSK through which LRP4 is known to signal.  While it is 
unknown whether caveolin-3 expression affects LRP4 in agrin activation and signal transduction, 
it is likely.  There are 3 putative caveolin binding domains on LRP4, which if LRP4 also binds to 
caveolin-3, support the idea of a caveolin-3 forming a scaffold and sequestering proteins required 
for efficient nAChR clustering.  Based on the results shown above (Figure 19), caveolin-3 is 
important for MuSK expression stability and agrin activation.  Thus, caveolin-3 may assist in the 
binding between and co-localization of MuSK and LRP4. 
Dishevelled-1 was another protein identified as essential for nAChR clustering resulting 
from interactions with MuSK (Luo, Wang et al. 2002).  While there is no difference in MuSK 
and dishevelled-1 association (Figure 23), it is feasible that lack of caveolin-3 affects the 
localization of both MuSK and disshevelled-1.  This would allow for association while still 
affecting signal transduction and MuSK phosphorylation.  This theory is supported by the strong 
association of MuSK and dishevelled-1 with caveolin-3 following 1 h of agrin treatment.  
Interestingly, antisense dishevelled-1 treatment led to a 40% decrease in nAChR clustering, 
which is not as strong as the 60% change found in caveolin-3 null myotube experiments (Figure 
10)(Luo, Wang et al. 2002).  Many other isoforms of LRPs are involved in the Wnt signaling 
pathway, as this is the canonical pathway though which dishevelled-1 acts.  The LRP4 
ectodomain does not bind to the Wnt1 ligand, but this does not preclude Wnt signaling through 
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MuSK (Zhang, Luo et al. 2008).  Further research is required to delineate a potential caveolin-3 
and MuSK signaling complex. 
The above research answers some questions while raising some new ones.  The results 
suggest a mechanism for the role of caveolin-3 in the signaling cascade leading to nAChR 
clustering (Figure 25).  In this model there is only full clustering in the agrin treated wildtype 
cells as evidenced by MuSK phosphorylation and MuSK and dishevelled-1 localization to the 
caveolae along with Rac1 which is activated as represented by binding GTP.  In agrin treated 
caveolin-3 null myotubes, there is some MuSK phosphorylation and association with 
dishevelled-1, but this never localizes to the same domain as Rac1 which remains unactivated.  
In the non-treated wildtype and nAChR there is no agrin signal to organize the co-localization 
and association of MuSK, dishevelled-1, and Rac1 with caveolin-3. 
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Figure 25. Proposed Model of nAChR Clustering 
These proposed mechanisms indicate the importance of caveolin-3 for MuSK and Rac1 activation and nAChR 
clustering, as identified in experiments in wildtype myotubes.  Non-agrin treated wildtype and agrin treated and 
untreated caveolin-3 null myotubes accordingly have abrogated nAChR clustering. 
This model is one dimensional and only looks at agrin signaling and myotubes, glossing 
over the complexity that actually occurs in neuromuscular junction organization.  As already 
stated, caveolin-3 null mice are viable but do not live as long as wildtype mice (Galbiati, 
Engelman et al. 2001).  The ability for forming functional neuromuscular junctions in these 
mice, probably results from the plethora of signals that have been identified as having small 
affects on nAChR clustering.  In muscle, neural agrin release leads to agrin embedding in the 
extracellular matrix, which does not occur when using the soluble agrin used in these 
experiments.   The effect of the cell media, especially the presence of serum may also alter 
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signaling pathways, would normally counterbalance each other or function simultaneously.  
Likewise, ACh signaling may reinforce nAChR localization and stability allowing for 
neuromuscular junction function.  These are all limitations of our model and most models used 
for nAChR clustering and organization of the post-synaptic membrane. 
The time course of nAChR clustering in our model is different from other published 
research.  MuSK phosphorylation and Rac1 activation occur between 15 m and 30 m in other 
studies (Luo, Wang et al. 2002; Weston, Gordon et al. 2003).   This may result from a number of 
factors.  Most nAChR clustering research uses only 1 or 2 cell lines that have been in culture for 
years.  This length of culturing may have enhanced some signaling processes, while eliminating 
redundant signaling.  Our immortalized cell lines are used with less than 30 passages.  The 
background of our myoblast lines may also alter signaling pathways.  Our cell culture model 
originates from crosses of either wildtype or caveolin-3 null transgenic animal with an immorto-
mouse containing a temperature sensitive SV40 large T antigen gene under an interferon-gamma 
promoter (Volonte, Peoples et al. 2003).  The immorto-mouse background myoblasts are 
conditionally proliferative when maintained at 33°C and under interferon-gamma. Ubiquitous 
expression of this gene may interfere with some signaling pathways, especially if it is not fully 
inactivated at 37°C (Whitehead, VanEeden et al. 1993).   The signaling differences may also 
result from the age of the mice from which the cultures are taken.  The wildtype and caveolin-3 
null myoblasts were obtained from adult mice between 8 and 10 months old, which may affect 
the overall speed of signal induction.  In both our cell culture model and previously studied cell 
culture models, the activation of certain proteins follows the same pathway even if there is a 
delay in the activation time course.  The delay in the nAChR clustering signal gives the benefit 
of identifying signaling patterns, correlating to ligand treatment but that do not fit the new 
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system.  JNK activation remains on par with JNK activation in other systems, suggesting an 
activation that is not through the agrin induction of the MuSK-Rac1 signaling cascade. 
The research in this chapter has delineated a role of caveolin-3 in signaling for nAChR 
clustering at the neuromuscular junction.  The varied associations of caveolin-3 with proteins 
involved in nAChR clustering, suggests a role for caveolin-3 in stability, localization, and 
efficiency of signaling pathway proteins.  This research implies changes in the formation of the 
post-synaptic membrane, but does not address if there are changes in actual neuromuscular 
junction function. 
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5.0  FUNCTIONAL CHANGES AT THE NEUROMUSCULAR JUNCTION 
5.1 INTRODUCTION 
The preceding chapters identify the loss of caveolin-3 expression as changing the 
organization of nAChR through disturbed nAChR clustering signaling.  While the lack of 
caveolin-3 expression visually changes the structure and localization of the post-synaptic 
membrane, there are limited data suggesting a functional significance.  Most neuromuscular 
junction functional data comes from case studies with EMG recordings and nerve conduction 
studies in patients with caveolin-3 mutations.  The identified structural neuromuscular junction 
changes may be: 1) cosmetic and not affecting function, 2) compensated for by subsequent 
structure changes, or 3) cause direct dysfunction of neuromuscular junction signaling.  The 
research presented here attempts to parse out the role of caveolin-3 in neuromuscular junction 
function. 
5.1.1 Limb-Girdle Muscular Dystrophy-1C 
Patients with caveolin-3 mutations have been diagnosed with LGMD-1C, rippling muscle 
disease, distal myopathy and hyperCKemia (Woodman, Sotgia et al. 2004).  EMG analysis of 
some patients with caveolin-3 mutations indicated myopathic characteristics, while other patients 
are described with unremarkable EMG results, as published in case studies.  The reported nerve 
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conduction studies (NCS) have been generally characterized as normal.  Myopathic EMGs are 
characterized by decreased amplitude and duration (Preston and Shapiro 2002).  
5.1.2 Caveolin-3 at the Neuromuscular Junction in Caenorhabditis elegans 
Research in Caenorhabditis elegans (C. elegans) with conserved caveolin-3 mutations 
has identified changes in nAChR activation after treatment with pharmacologic agents.  There 
are 2 caveolin isoforms in C. elegans.  C. elegans caveolin-2 is similar to mammalian caveolin-2, 
while C. elegans caveolin-1 gene is equally homologous to both mammalian caveolin-1 and 
caveolin-3.  Caveolin-1 was found to co-localize with the C. elegans nAChR-alpha subunit 
UNC-63 at the post-synaptic membrane and does not co-localization with pre-synaptic 
membrane markers.  While there is also expression of C. elegan’s caveolin-1 protein in the worm 
nervous system, it is not localized to the neuromuscular junction.   Levamisole treatment of 
caveolin-1 mutated worms hastened the paralytic response.  Caveolin-1 null worms replicated 
the levamisole response, though siRNA knockdown of caveolin-1 had no effect supporting a 
caveolin-1 role in neuromuscular junction formation.  Disruption or abrogation of caveolin-1 
expression in worms leads to a compromised neuromuscular junction as identified by faster 
paralysis from nAChR agonists.  The effect of caveolin-1 on the worm neuromuscular junction is 
not delineated, but caveolin gene conservation from worms to mice and humans supports the 
idea of a mammalian caveolin-3 affect on neuromuscular junction function (Parker, Peterkin et 
al. 2007). 
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5.1.3 Neuromuscular Regulation of Muscle Contraction 
While these experiments will focus most on nerve to muscle signaling it is important to 
understand the whole signaling process from the action potential in the nerve to muscle 
contraction (Figure 26).  Signal transduction from the motor neuron to muscle contraction is 
highly efficient but also very complex.  It achieves both of these characteristics primarily with 
voltage fluctuation.  To outline the process, an action potential travels from the motor-neuronal 
cell body down the motor neuron axon by successive sodium influx depolarization.  Upon 
reaching the nerve terminal, the depolarization signal changes from sodium influx to calcium 
influx.  This calcium influx induces ACh release from neurotransmitter filled vesicles fusing 
with the membrane at the active zones of the nerve terminal.  The ACh diffuses across the 
synapse and binds to nAChR which initiates sodium influx through the nAChR channel. This 
influx is enhanced by activation of the voltage gated sodium channels at the troughs of the 
neuromuscular junction. The sodium depolarization spreads along the sarcolemma, eventually 
reaching the T-tubules.  The T-tubules are membranous tubules that facilitate simultaneous 
signaling to all the myofibrils in the myofiber, propagating coordinated contractions.   
Depolarization originating at the sarcolemma induces calcium release at the T-tubules through 
the dihydropyridine receptor (DHPR).  The DHPR calcium release induces a stronger subsequent 
calcium release from the sarcoplasmic reticulum through a voltage gated calcium receptor also 
known as ryanodine receptor.  This high calcium concentration causes removal of tropomyosin 
from binding myosin, freeing the myosin and actin filaments which by using adenosine 
triphosphate energy, slide across each other contracting the muscle. 
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Figure 26. Diagram depicting the Neuromuscular Regulation of Muscle Contraction  
The complex signaling of muscle contraction.  1) The action potential travels down the nerve axon by sodium 
depolarization.  2) At the nerve terminal the sodium depolarization induces calcium depolarization. 3) The calcium 
influx induces ACh release from vesicles in the nerve terminal.  4) The ACh travels across the synapse and binds the 
nAChR causing sodium influx through the nAChR. 5) nAChR sodium influx activates the sodium depolarization 
through voltage gated channels (green dots).  6 and 7) Sodium depolarization continues down the sarcolemma and 
into the T-tubules (dark blue) by voltage gated sodium channels. 8) Sodium depolarization in the T-tubules induces 
dihydropyridine receptor calcium release 9) Dihydropyridine receptor calcium release induces calcium release from 
the sarcoplasmic reticulum (orange covering the myofibrils) through voltage gated calcium channels called 
ryanodine receptors. This calcium release induces muscle contraction by allowing actin and myosin fibers to 
associate and slide against each other in the myofibril. Solid arrows = sodium depolarization, Dotted arrows = 
Calcium depolarization 
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5.1.4 Diseases of the Neuromuscular Junction 
Several diseases found to directly affect neuromuscular junction signaling are Lambert-
Eaton Myasthenic Syndrome (LEMS), Myasthenia Gravis (MG) and Congenital Myasthenia 
Syndrome (CMS).   These diseases are characterized by weakness, but unlike muscular 
dystrophies, there is not progressive muscle wasting.  The severity of LEMS and MG symptoms 
fluctuates daily (Vincent 2008).   
MG and CMS are similar diseases resulting in easy muscle weakness and fatigue, but 
differ in disease origination.  MG is an autoimmune syndrome targeting proteins involved in the 
clustering of the nAChR at the post-synaptic muscle membrane.  MuSK, rapsyn and nAChR are 
often the targeted proteins.  Antibody binding of these proteins induces degradation, disruption 
of the nAChR organization, and decrease the overall number of nAChR for neuromuscular 
signaling.  The loss of nAChR makes the muscle more susceptible to fatiguing during repetitive 
movement.  CMS has the same results of MG except that the disease characteristics result from 
protein mutations affecting nAChR clustering and not from auto-immune disruption 
(Boonyapisit, Kaminski et al. 1999).  
LEMS disrupts the pre-synaptic terminal by autoimmune response, disrupting ACh 
release.  Most of the time the protein targeted by the disease is the voltage gated calcium 
channel, which is required for ACh release.  This channel responds to axonal depolarization 
reaching the nerve terminal. This calcium influx induces proportional acetylcholine release 
which activates the post-synaptic muscle contraction signal.  The loss of these pre-synaptic 
calcium channels leads to decreased acetylcholine release and weak or non-existent muscle 
response.  Continual nerve firing plies the nerve terminal with extra calcium leading to increased 
acetylcholine release and increased strength of contraction (Takamori 2008). 
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5.1.5 Analysis of Neuromuscular Diseases 
EMG is often used to delineate the characteristics of neuromuscular diseases.  The 
readout is the electromyogram (EMG), or depiction of voltage change over time in a wave form, 
which can be quantified.  EMG procedure in patients refers to electrode placement in the muscle 
and also measuring muscle depolarization after voluntary contraction or intramuscular nerve 
stimulation.  Nerve conduction studies are studies measuring traveling of the action potential 
along the nerve and are done to discount neuropathic disease.  EMG and NCS are performed 
simultaneously to get a full picture of muscle depolarization and nerve signaling in 
neuromuscular diseases (Preston and Shapiro 2002).  Repetitive low frequency stimulation in 
MG and CMS patients, often yields a decrease of 10% or larger from the 1st to the 5th stimuli of 
the EMG  amplitude or area under the curve (Vincent 2008).  This generally results from an 
overall decrease in nAChR at the neuromuscular junction due to an autoimmune reaction or 
disrupted nAChR clustering.  Under these conditions there is not enough nAChR available for 
subsequent activation due to inactivation of the recently activated nAChR leading to a decrement 
in signaling.  In LEMS electromyography, there is an increment in the EMG amplitude under 
high intensity and frequency stimulation (Takamori 2008).  Increased calcium influx at the nerve 
terminal under high frequency stimulation primes the nerve terminal with calcium allowing 
excessive release of acetylcholine.  This increment is highest after exercise. 
Using EMG studies along with concomitant measurement of contractile force, these next 
experiments will analyze neuromuscular junction function and the subsequent contraction in 
wildtype and caveolin-3 null mice.  
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5.1.6 Experimental Set-up 
Differences in the neuromuscular function between wildtype and caveolin-3 null mice 
were analyzed by EMG.  For these experiments, the mice were anesthetized using urethane and 
shaved at the neck and the hind half of the mouse to maintain aseptic conditions (Figure 27).  
First, the trachea was isolated and a tracheotomy tube inserted to assist in breathing.  Next, the 
skin around the ankle was cut and the Achilles tendon exposed.  This tendon was cut and tied by 
string to a force transducer to measure contractile force.  The foot was restrained to have 
maximal muscle contractile strength readings.  The skin covering the hind left quarter was 
opened in a horizontal laceration and by spreading the muscle the sciatic nerve was isolated.  The 
skin flaps were tied up forming a pool for mineral oil to maintain viability of the nerve.  A 
bipolar stimulating electrode was placed under the nerve and the nerve was cut at the most 
proximal point to eliminate reflex responses. A recording electrode was inserted into the 
gastrocnemius muscle through a slit in the skin.  In these experiments the nerve was stimulated at 
the sciatic nerve, and the subsequent muscle electromyogram and force of muscle contraction 
measured. 
Figure 27. Diagram of the mouse Set-up for EMG and Contractile Strength Experiments 
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5.2 RESULTS 
5.2.1 EMG Data Analysis 
The EMG results can be analyzed individually per stimulation or as a series of events.  In 
terms of the MG, CMS, and LEMS, the most telling results are the series of stimulations which 
show either decreased or potentiation of muscle depolarization (Vincent 2008).  The 
experimental results did not provide distinct differences found in MG, CMS, and LEMS, in 
terms of a decrease or increase upon repetitive nerve stimulation (Data not shown).   The EMG 
data were analyzed for a number of factors including latency, amplitude, area under the curve, 
stimulation to peak and the ratio of amplitude to area under the curve (Figure 28). 
Figure 28. Representative EMG Wave and Associated Data 
Low frequency nerve stimulation induces subsequent muscle depolarizations, which produces a wave form such as 
the representative wave above.  This research analyzes data points collected from each wave including the latency, 
(blue arrow) area under the curve (purple fill), amplitude (green arrow), stimulation to peak (orange arrow) and the 
ratio of amplitude to area under the curve. 
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5.2.2 Latency of EMG Stimulation 
Latency is the measure of time from nerve stimulation to the beginning of muscle 
depolarization.  The time of the stimulus is identified as the EMG artifact that shows up in the 
EMG recording ahead of actual muscle depolarization.  Comparison of the latency between 
wildtype and caveolin-3 null animals indicated a significant delay between stimulation and 
muscle depolarization in the caveolin-3 null animals (Figure 29).  As this time period covers the 
time from nerve stimulation to muscle sarcolemma depolarization, this may be representative of 
changes at the neuromuscular junction.  If these neuromuscular junctions are differentially 
organized then it should affect the latency and therefore the efficiency of transmission. 
 
Figure 29. Latency of EMG Stimulation 
EMG analysis of the latency of stimulation at 10V and 1Hz in wildtype (WT) and caveolin-3 null (KO) animals. 
Box and whisker plots, where the box represents the interquartile range, while the top and bottom of the bar, 
represents the full range.  The dot indicates the average latency length. WT n=2, KO n=4 Student’s T-test * p < 
0.0001. Figure was originally published in MBC (Hezel, de Groat et al. 2009). 
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5.2.3 Amplitude of the EMG 
The amplitude represents the total voltage change during the depolarization and 
repolarization.  The amplitude was calculated as the voltage change below and above baseline.  
While the amplitude in the wildtype mice was well conserved across specimens, the caveolin-3 
null mice had significant variability (Figure 30).  The voltage decrease resulted from less muscle 
depolarization in the area of the recording electrode, which may come from sub-maximal 
activation through the neuromuscular junction.  There is a possibility that this is an artifact from 
muscle wasting with a loss of depolarization in neighboring myofibers. 
 
Figure 30. Amplitude of the EMG 
EMG analysis of the amplitude of the muscle depolarization at 10V and 1Hz in wildtype (WT) and caveolin-3 null 
(KO) animals. Box and whisker plots, where the box represents the interquartile range, while the top and bottom of 
the bar, represents the full range.  The dot indicates the average latency length. WT n=2, KO n=4 Student’s T-test * 
p < 0.0004. Figure was originally published in MBC (Hezel, de Groat et al. 2009). 
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5.2.4 Area Under the Curve of the EMG 
The area under the curve is a composite of the time period of the depolarization and the 
amplitude of the first peak.  This is a correlate of the strength of depolarization over 
depolarization time in muscle fiber analyzed.  There is significantly less depolarization in the 
caveolin-3 null mice (Figure 31).  This may result from the decreased activation in correlation to 
the amplitude changes.  This may also represent changes in the depolarization characteristics of 
the muscle, with decreased opening of the voltage gated sodium channels activated by sodium 
influx through the nAChR. 
 
Figure 31. Area Under the Curve of the EMG 
EMG analysis of the area under the curve at 10V and 1Hz in wildtype (WT) and caveolin-3 null (KO) animals. Box 
and whisker plots, where the box represents the interquartile range, while the top and bottom of the bar, represents 
the full range.  The dot indicates the average latency length. WT n=2, KO n=4 Students’s T-test * p < 0.0001.  
Figure was originally published in MBC (Hezel, de Groat et al. 2009). 
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5.2.5 Time from Stimulation to Peak 
Stimulation to peak analyzes the activation characteristics of the muscle depolarization.  
Since there is a longer latency in the caveolin-3 null mice, if all other characteristics were the 
same one would expect this to be reflected in the time from stimulation to peak (Figure 29).  
There is no significant difference in the time from latency to peak between wildtype and 
caveolin-3 null mice (Figure 32).  These results further confirm changes found in the amplitude 
and area under the curve as affecting depolarization. 
 
Figure 32. Average Time from Stimulation to Peak of the EMG 
EMG analysis of the average time from the nerve stimulation until the peak in muscle depolarization at 10V and 
1Hz in wildtype (WT) and caveolin-3 null (KO) animals. Height of the column represents the average.  Error bars 
are standard error of measure (SEM). WT n=2 SEM = 0.038, KO n=4 SEM = 0.038, Student’s T-test * p < 0.1711.  
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5.2.6 Ratio of Amplitude to Area Under the Curve 
The ratio of amplitude to area under the curve analyzes changes in the EMG wave 
characteristics.  The ratio reflects the correlation between the amplitude and area under the curve.  
When amplitude decreases a consequent decrease in area under the curve is expected.  Our 
results show that the overall waves have similar characteristics reflecting the strength of 
depolarization (Figure 33).  Though insignificant the changes in area of caveolin-3 null animals 
are not directly proportional to the amplitude, as exemplified by a ratio of 1.2 as opposed to a 
ratio of 1 in wildtype. 
 
Figure 33. Ratio of Amplitude to Area Under the Curve of the EMG 
Ratio of the amplitude to the area under the curve of the EMG at 10V and 1Hz in wildtype (WT) and caveolin-3 null 
(KO) animals. Height of the column represents the average.  Error bars are standard error of measure (SEM). WT 
n=2 SEM = 0.042, KO n=4 SEM = 0.082, Student’s T-test * p < 0.1711.  
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5.2.7 Overall EMG Analysis 
Compiled in Table 3 is the numerical data for the EMG results represented above.  The 
latency, amplitude and area under the curve results were significant.  The latency difference 
between wildtype and caveolin-3 null animals suggests a delay in muscle depolarization 
following nerve stimulation potentially representing changes in neuromuscular junction 
transmission.  The changes in amplitude and area under the curve could reflect neuromuscular 
transmission changes or subsequent changes in the process of muscle depolarization.  The 
changes in the amplitude and area under the curve may also reflect changes in channel activation 
and inactivation in muscle as alternative effects of the loss of caveolin-3 expression. 
Table 3. EMG Results  
 
5.2.8 Contraction Results 
Muscular dystrophies are characterized by muscle weakness therefore concomitant 
analysis of contractile strength with NCS seemed appropriate.  These animals are a model of 
LGMD-1C, a mild form of muscular dystrophy. 
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While data were collected at different intensities and frequencies of activation, muscle 
contraction was mostly similar between wildtype and caveolin-3 null mice.  Distinct differences 
in the contractile consistency were identified under tetanic stimulation (Figure 34).  Under 
continuous 50 Hz stimulation, there are stability differences between wildtype and caveolin-3 
null mice.  The wildtype contraction peaks and plateaus for 5-6 s and then runs down.  The 
contraction tension is relatively steady with only slight variability in contractile force.  In the 
caveolin-3 null mouse, contractile force reaches an initial peak, continues to climb over the next 
6-8 s and then runs down.  The force of this contraction is unstable as evidenced by the variation 
in contraction tension.  This is easily identifiable in the snippet from the first 2 seconds of the 
contractile force measurement (Figure 35).  Calculation of the area of the contraction variability 
identifies the caveolin-3 null mice tetanic contraction as being twice as unstable as the wildtype 
contractions (Figure 36). 
Figure 34. Tetanic Muscle Contractions at 100V and 50Hz for 20 seconds. 
Representative contractile force recordings from the gastrocnemius muscle of wildtype (WT) and caveolin-3 null 
(Cav-3 null) animals obtained during 20 s of 100V and 50 Hz continuous sciatic nerve stimulation.  Figure was 
originally published in MBC (Hezel, de Groat et al. 2009). 
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Figure 35. Snippet of the first 500 ms of the above Tetanic Contractions 
This is a short snippet of the above continuous contraction, showing the variability in continuous muscle strength in 
the caveolin-3 null (Cav-3 null) tetanic contraction as compared to wildtype (WT). Figure was originally published 
in MBC (Hezel, de Groat et al. 2009). 
Figure 36. Quantification of the Instability of Tetanic Muscle Contraction 
The variable portion of the tetanic contraction recording was measured as the average trace area per second of 
recording and compared between wildtype (WT) and caveolin-3 null (KO) animals.  Error bars represent SEM. n=7 
Student’s T-test * p < 0.0034. Figure was originally published in MBC (Hezel, de Groat et al. 2009). 
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5.3 DISCUSSION 
The research presented here analyzes the functional characteristics of the neuromuscular 
junction.  The stimulation latency, the amplitude, and area under the curve of the EMG are 
significantly changed between wildtype and caveolin-3 null mice.  Two other factors, stimulation 
to peak and the ratio of the amplitude to area under the curve are not significant but further our 
understanding of neuromuscular junction transmission.  Analysis of the contractile differences 
between wildtype and caveolin-3 null mice showed decreased stability of tetanic contraction in 
caveolin-3 null animals.  While the whole of muscle contraction signaling occurs before 
contraction, this indicates a disruption in contractile signaling, though not specific to the 
neuromuscular junction.  There is also potentiation of contractile strength in the tetanic 
contraction of the caveolin-3 null mice, which is discussed later in this chapter. 
These experiments were conducted in animals, housed under identical conditions and 
were also non-survival, which is not acceptable for humans.  The animals were all age matched 
in the C57BL/6 background and had identical cage conditions throughout life.  The standardized 
conditions allowed for the detection of subtle differences.  While the results between these 
animal strains are distinct, these differences might not be detectable in humans, where patient 
variability is larger.  Isolation of the nerve and removal of reflex signaling were also important to 
parsing out the subtle differences and these techniques would need to be modified for patients. 
Latency also reflects the length of the sciatic nerve to the nerve terminal and the 
conduction characteristics.  While there may be slight variations in this length from muscle 
innervations at the knee to the nerve terminal, the stimulating electrode was placed directly 
between the knee innervations and the nerve threading through the pelvic bone.  The differences 
in latency between wildtype and caveolin-3 null animals are indicative of signal disruption 
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before muscle depolarization.  It is possible that this could be resultant of pre-synaptic signaling 
differences, but since there is no caveolin-3 expression in the nerves it is unlikely that lack of 
caveolin-3 would affect neuronal signaling.  Caveolin-3 immunoreactivity is found in the 
Schwann cells forming the myelin sheath around the axon, but caveolin-1 is the predominant 
caveolin expressed (Kawahara 2004). 
The myasthenic syndromes described above are easily identified by EMG tests, since the 
results are based on internal controls.  The results compare the amplitude or area under the curve 
of the 5th EMG to the first EMG, removing variability between subjects.  The EMG differences 
identified in our experiments unlike with the myasthenic syndromes would require a control 
group for comparison.  Human variability may not allow subtle differences of this nature to be 
readily determined.  More research will need to be done to resolve whether these changes can 
actually be detected in humans.  This may require new testing techniques, the use of 
pharmacological agents, or both for testing viability in human subjects.  Procedures removing the 
requirement of a control group such as those already used in the neuromuscular junction analysis 
of the various myasthenia diseases, would be ideal.      
The determination of neuromuscular junction diseases depends on a decrement or 
increment in EMG amplitude or area under the curve during repetitive stimulation.  Myopathic 
diseases are diagnosed by EMG changes in amplitude, duration and jitter.  There is overlap in the 
data used in determination of neuromuscular junction diseases and myopathic diseases.  Whether 
the EMG data is really describing neuromuscular transmission differences or muscle degradation 
remains to be reevaluated (Chapter 6). 
Analysis of muscle contraction found distinct differences under tetanic, or constant 
contraction. This raises several questions.  Does this result from changes in neuromuscular 
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junction structure?  What is the reason behind the differences in contractile stability?  What is the 
meaning of the potentiation in the muscle contraction?  Are there subcellular locations where 
caveolin-3 loss affects signaling from nerve to muscle contraction and potentiation? 
The answer to these questions will require further research, but based on current research 
we can draw some conclusions.  Our research on the structural differences of the nAChR clusters 
found more diffuse distribution of nAChR in the caveolin-3 null mice as compared to wildtype.   
If the nAChR is diffusely spread along the sarcolemma at the neuromuscular junction and the 
nerve terminal doesn’t compensate with a larger nerve terminal then it would place some nAChR 
outside juxtaposition from the nerve terminal.  Under tetanic contraction with continual ACh 
release, ACh would leak outside of the synapse and localization of acetylcholineesterase, 
activating extra-synaptic nAChRs not activated under regular contractions.  Activation of extra-
synaptic nAChR might explain the contractile potentiation in caveolin-3 null mice.  The 
instability of contractile tension may also result from overall disruption of the nAChR clustering 
structure.  These structural changes may stem from changes in protein localization and more 
importantly, nAChR in relation to the voltage gated sodium channels and changes in the mature 
neuromuscular junction post-synaptic membrane folding characteristics.  Analysis of the ultra-
structure of the neuromuscular junction in caveolin-3 null mice could identify neuromuscular 
junction structural changes. 
In the introduction of this chapter the signaling leading to muscle contraction was 
diagrammed.  There are other places outside of the neuromuscular junction where loss of 
caveolin-3 may affect contractile signaling. 
Caveolin-3 is located along the sarcolemma so it may affect the muscle depolarization.  
Caveolin-3 has been shown to bind several ion channels.  Since many of the signals involved in 
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muscle contraction involve ion flux, lack of caveolin-3 may also affect this signaling.  Caveolin-
3 has been indentified to associate with the sodium potassium pump in the sarcolemma 
(Kristensen, Rasmussen et al. 2008).  Exercise induced greater localization of caveolin-3 and the 
alpha-subunits of the sodium pump to the sarcolemma.  Potassium voltage dependant channels, 
Kv1.3 and Kv1.5 have been shown to co-fractionate and co-localize with caveolin-3 (Folco, Liu 
et al. 2004; Martinez-Marmol, Villalonga et al. 2008).  Sodium voltage dependant channel 
Nav1.5 has also been seen to co-localize with caveolin-3 in cardiomyocytes (Palygin, Pettus et 
al. 2008).  Changes in the opening and closing characteristics of the voltage gated sodium 
channels would change amplitude and area under the curve data of the EMG. It is possible that 
lack of caveolin-3 affects channel dynamics. 
Caveolin-3 localization to the T-tubules in mice throughout life, may also affect 
contractile signaling.  Parton et al. (1997) show caveolin-3 involvement in T-tubule formation in 
cultured myotubes and muscle, with a postnatal co-localization decrease as determined by 
immunofluorescence.  Consequently, dihydropyridine receptor co-localization with caveolin-3 
was lost as differentiation progressed (Parton, Way et al. 1997).   Research also suggests 
caveolin-3 T-tubule localization in mature muscle fibers by immunofluorescence and electron 
microscopy (Ralston and Ploug 1999). This was confirmed by stripping off the sarcolemma to 
find caveolin-3 localization at the T-tubules in the myofibrils that make up the muscle (Murphy, 
Mollica et al. 2009).  The localization of dihydropyridine receptors at the T-tubule is disturbed in 
caveolin-3 null muscle.  Ultra-structural analysis of T-tubules shows a change from a transverse 
linear localization in wildtype muscle to a disordered cluster form in caveolin-3 null muscle 
respectively (Galbiati, Engelman et al. 2001).   
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Caveolin-3 mutations are also associated with rippling muscle disease.  In this disease, 
severe contraction will lead to a rippling contraction through the muscle.  EMG analysis of 
rippling muscle has determined that rippling muscle is electrically silent, pointing to a defect in 
the T-tubules as muscle depolarization is not recorded by EMG.  This supports a caveolin-3 role 
in T-tubule signaling in addition to the changes at the neuromuscular junction. 
Calcium channels are important to the last signaling steps in muscle contraction with 
sequential calcium release from the dihydropyridine receptors then the ryanodine receptor 
induced by T-tubule depolarization.  Both isoforms CaV1.1 and CaV1.2 of the dihydropyridine 
sensitive voltage gated L-type calcium channels are expressed in muscle.  CaV1.2, which is not 
particular to skeletal muscle cells, is expressed at the plasma membrane and functions in calcium 
signaling by activating calcium binding proteins (Jeftinija, Wang et al. 2007).  Of these slow 
activating and inactivating channels, CaV 1.2 is localized to type I and type IIa fibers but not 
type IIb, while CaV1.1 is ubiquitous throughout the muscle fibers (Couchoux, Allard et al. 2007; 
Jeftinija, Wang et al. 2007).  Immunofluorescence indicated that CaV1.2 partially co-localized 
with caveolin-3 and partially co-localized with dystrophin (Jeftinija, Wang et al. 2007).  
Immunofluorescence of wildtype myotubes and caveolin-3 transfected myoblasts shows co-
localization of CaV1.1 and caveolin-3 at the plasma membrane and the developing T-tubules.  
Myotubes expressing the dominant negative caveolin-3 mutant have decreased CaV1.1 
expression and decreased current permeability (Couchoux, Allard et al. 2007; Weiss, Couchoux 
et al. 2008).  Caveolin-3 mutant transfected myotubes had varied current required for channel 
activation but overall the current was decreased (Weiss, Couchoux et al. 2008). 
Our experiments find EMG and contractile force differences between wildtype and 
caveolin-3 null mice.  EMG analysis indicates differences in the latency, amplitude and area 
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under the curve between the animal strains.   This supports the findings of disrupted nAChR 
clustering and disrupted mechanism leading to nAChR clustering identified in the previous 
chapters.  These results will need to be independently verified. 
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6.0  CONCLUSION 
The data presented here identify a role for caveolin-3 in nAChR clustering.  Agrin 
treatment of wildtype myotubes leads to essential nAChR clustering steps of MuSK 
phosphorylation and Rac1 activation.  These signaling processes occur when temporally bound 
to caveolin-3.  Agrin treatment of caveolin-3 null myotubes induces some phosphorylation of 
MuSK, while Rac1 activation by agrin is abrogated.  These changes in signaling are reflected in 
the clustering differences between wildtype and caveolin-3 null myotubes.  Agrin induced 
clustering in caveolin-3 null myotubes is reduced by more than half and the clusters are more 
diffuse across the membrane.  This in vitro research indicated distinct differences in nAChR 
clustering and organization of the neuromuscular junction between wildtype and caveolin-3 null 
myotubes.  The results of figure 5, modeled the differences in the nAChR clusters at the muscle 
sarcolemma, where the nAChR is distinct in wildtype mice and more diffuse in caveolin-3 null 
mice (Figure 2 and 3).  These changes indicated differences in the neuromuscular junction 
function between wildtype and caveolin-3 null mice.  Subsequent, EMG studies indicated a 
significant longer latency from the stimulation artifact to the EMG recording as well as 
decreased amplitude and area under the curve in caveolin-3 null mice as compared to wildtype 
mice.  These differences correspond to a myopathic disease. 
If the differences identified appear to be specific to the neuromuscular junction, why do 
these results fall under myopathies instead of neuromuscular junction diseases such as LEMS, 
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MG and CMS, which also have changes in the pre- or postsynaptic junction?  To answer this it is 
important to look at the whole neuromuscular junction structure and function to understand the 
EMG results. 
Revisiting the muscle contraction signaling diagram, the EMG recording reflects half of 
the signaling in the muscle up to depolarization of the sarcolemma.  It is unlikely that EMG 
changes in caveolin-3 null mice reflected the nerve action potential leading to pre-synaptic ACh 
release.  There was no caveolin-3 expression in the nerve and stimulation was supra-maximal, or 
well above the nerve transmission threshold.  The EMG differences could therefore result from 
nAChR activation or subsequent muscle depolarization. 
While there do not appear to be differences in the number of nAChR, it is possible that 
ACh binding to the receptor and subsequent activation is delayed.  This hypothesis would 
correspond to the increased latency.  Other studies have analyzed nAChR activation by patch 
clamp in myotubes cultured from biopsies obtained from normal and DMD patients.  The DMD 
cultures did not have any changes in the influx and opening characteristics but there was an 
overall increase in frequency of channel opening.  These results are attributed to increased ACh 
release, but possibly suggest changes in depolarization and repolarization characteristics 
(Mancinelli, Sardini et al. 1989).  It is possible that the caveolin-3 mutation disrupts the channel 
mechanics, through changed characteristics of the nAChR clustering. 
Alternatively, the changes in EMG results are derived from altered sodium depolarization 
of the myotube.  Since nAChR activation is required to reach threshold before opening of the 
voltage gated ion channel, this may play a role in the change in the latency and depolarization.  
The change could also result from decreased numbers of voltage gated sodium channels at the 
neuromuscular junction.   A recently published manuscript by Banks et al. (2009), suggests that 
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reduction in the folds at the neuromuscular junction membrane reduces the number of sodium 
channels.  Caveolin-3 null mouse muscle 3D images of nAChR localization in muscle cross-
sections, support this occurrence in decreased amplitude and area under the curve by EMG.  The 
3D image of wildtype NMJ is much more dynamic then the very planar caveolin-3 null mouse 
neuromuscular junction (Figure 3).  Caveolin-3 has been shown to assist in sodium 
depolarization in cardiomyocytes.  Addition of caveolin-3 antibodies to the cytoplasm of cardiac 
myocytes abrogated isoproterenol induction of the voltage gated sodium channel (Yarbrough, Lu 
et al. 2002).  Another factor that may play a role in the EMG results is myofiber size variability.   
There are multiple possibilities for the weaker depolarization in some caveolin-3 null cells. 
Overall, the loss of caveolin-3 decreases sarcolemma sodium depolarization either 
through changes in nAChR activation characteristics or changes in the number or resistance of 
voltage gated sodium channels in the sarcolemma.  This leaves open the question of whether the 
structural and signaling deficiencies shown here contribute to muscle degradation, or if 
neuromuscular junction structural and transmission changes and muscle degradation are 2 
separate occurrences. 
This research uses these caveolin-3 null mice as a model for LGMD-1C.  LGMD-1C 
results from an autosomal dominant mutation of caveolin-3. In published case studies, patients 
with caveolin-3 mutations have been shown to have both normal and myopathic EMGs, and 
present with or without muscle weakness.  Progression heterogeneity in this disease could arise 
for many reasons.   This heterogeneity could result from genotypic variability, the caveolin-3 
mutations themselves, or differences in the lifetime of movement reflecting neuromuscular 
transmission changes.  In several studies the patients, do not present with weakness but do have 
myopathic changes.  This was found in both younger patients and some older patients.  This 
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supports our findings in mice of different EMG results without definitive weakness, and also 
corresponds with our muscle contractile results which are not weakened.  Due to the 
heterogeneity of the mutations involved, this may be mutation specific. 
This research finds structural disruption at the neuromuscular junction leading to 
myopathic EMGs.  There are other proteins which lead to disruption in the neuromuscular 
junction formation.  Many of the genes associated with the dystrophin-glycoprotein complex, 
lead to structural changes in the neuromuscular junction.  Loss of dystrophin which is 
characteristic of DMD leads to disrupted neuromuscular junction formation (Lyons and Slater 
1991).  Truncated dystrophins identified to prevent muscle degeneration were analyzed for their 
effect on neuromuscular junction formation in transgenic mice.  The truncated protein called 
minidystrophin led to proper neuromuscular junction formation, while the other, microdystrophin 
still underwent neuromuscular junction fragmentation, though temporally with formation of 
ringed fibers (Banks, Chamberlain et al. 2009).   Ringed fibers are a normal occurrence found in 
muscle as people age.  Utrophin, is the protein homologous to dystrophin and is associated with 
the neuromuscular junction.  Mice deficient in utrophin develop decreases in the density of the 
neuromuscular junction and associated membrane folding (Grady, Merlie et al. 1997).  Analysis 
of alpha-dystrobrevin, a cytoplasmic protein of the dystrophin glycoprotein complex, indicates a 
requirement for neuromuscular junction maturation (Grady, Zhou et al. 2000).  Loss of these 
genes leads to neuromuscular junction structure disruption.  These animal models would be a 
good place to start identifying whether general neuromuscular junction changes lead to 
myopathic EMG. 
The other possibility is that caveolin-3 is the driving factor behind the myogenic changes 
at the neuromuscular junction.  This is supported by the disruption of nAChR and the potential 
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association of caveolin-3 with voltage-gated sodium channels.  The EMG results could be a 
singular result due to the ubiquitous expression of caveolin-3 in the sarcolemma and muscle.  
Caveolin-3 binds to several proteins implicated in other forms of muscular dystrophy, such as 
Trim 32, dysferlin and proteins associated with the dystrophin-glycoprotein complex.   Some of 
these proteins also fall in the disruption of the neuromuscular junction category.  There is the 
possibility that these proteins could also affect the EMG results. 
Our research indicates that lack of caveolin-3 disrupts the post-synaptic membrane of the 
neuromuscular junction and that this is also associated with myopathic EMG.  Further research 
will need to be done to determine if this is a precursor to muscular degeneration and if this is 
applicable to multiple forms of muscular dystrophy.  If this is a common precursor to muscular 
degeneration, then treatments which rectify EMG efficiency should be a future target for 
treatment of muscular dystrophies.  These treatments may require delineation of whether EMG 
changes result from changes in nAChR channel functioning characteristics and/or muscle 
depolarization. 
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